WO2021161119A1

WO2021161119A1 - System and method for coordinating negative pressure and instillation therapy

Info

Publication number: WO2021161119A1
Application number: PCT/IB2021/050618
Authority: WO
Inventors: Brett L. Moore; Shannon C. Ingram; Justin Rice
Original assignee: Kci Licensing, Inc.
Priority date: 2020-02-10
Filing date: 2021-01-27
Publication date: 2021-08-19

Abstract

A system for providing negative pressure therapy at a tissue site. The system comprises: i) a primary therapy controller; ii) a first dressing interface configured to be controlled by the primary therapy controller and to provide at least one of first negative pressure therapy or first instillation therapy at the tissue site; iii) a secondary therapy controller configured to be controlled by the primary therapy controller; and iv) a second dressing interface configured to be controlled by the secondary therapy controller and to provide at least one of second negative pressure therapy or second instillation therapy at the tissue site.

Description

SYSTEM AND METHOD FOR COORDINATING NEGATIVE PRESSURE AND INSTILLATION THERAPY

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority to U.S. Provisional Application No. 62/972,441, filed on February 10, 2020, which is incorporated herein by reference in its entirety.

TECHNICAL FIELD

[0002] The invention set forth in the appended claims relates generally to tissue treatment systems and more particularly, but without limitation, to systems and methods for remotely controlling negative-pressure therapy systems.

BACKGROUND

[0003] Clinical studies and practice have shown that reducing pressure in proximity to a tissue site can augment and accelerate growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but it has proven particularly advantageous for treating wounds. Regardless of the etiology of a wound, whether trauma, surgery, or another cause, proper care of the wound is important to the outcome. Treatment of wounds or other tissue with reduced pressure may be commonly referred to as "negative-pressure therapy," but is also known by other names, including "negative- pressure wound therapy," "reduced-pressure therapy," "vacuum therapy," "vacuum-assisted closure," and "topical negative-pressure," for example. Negative-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro deformation of tissue at a wound site. Together, these benefits can increase development of granulation tissue and reduce healing times.

[0004] There is also widespread acceptance that cleansing a tissue site can be highly beneficial for new tissue growth. For example, a wound can be washed out with a stream of liquid solution, or a cavity can be washed out using a liquid solution for therapeutic purposes. These practices are commonly referred to as "irrigation" and "lavage" respectively. "Instillation" is another practice that generally refers to a process of slowly introducing fluid to a tissue site and leaving the fluid for a prescribed period of time before removing the fluid. For example, instillation of topical treatment solutions over a wound bed can be combined with negative-pressure therapy to further promote wound healing by loosening soluble contaminants in a wound bed and removing infectious material. As a result, soluble bacterial burden can be decreased, contaminants removed, and the wound cleansed.

[0005] However, the size, location, and etiology of wounds may vary widely. This leads to the use of diverse types of negative-pressure wound therapy (NPWT) systems and instillation therapy systems that are customized to one degree or another to the type of wound being treated. For example, a negative therapy wound dressing used to treat a “clean” surgical incision on a forearm is likely to be considerably smaller than a negative therapy wound dressing used to treat a large deep bruise and/or laceration on the chest caused by blunt force trauma. This customization extends to the controllers implemented in the negative therapy wound dressing, the operator interface(s), the physical connections to an external therapy control system, and the communication interfaces connecting the wound dressing, the operator interface, and the external therapy control systems. Such customization greatly increases equipment costs and may also increasing training costs for the operator.

[0006] Moreover, in some situations, a patient may have multiple, non-contiguous wounds or very large wounds that require the use of two or more negative-therapy wound dressings. To address these situations, clinicians have used a technique known as bridging in which two or more wound dressings are connected by tubing (i.e., bridging) such that instillation and negative pressure therapy are applied together via a single external therapy control system to the multiple wound dressings. However, there are significant limits to the use of bridging techniques.

[0007] Bridging is generally limited to neighboring, non-contiguous wounds. If the multiple non-contiguous wounds are too distant from each other, it may not be possible to bridge the wound dressings. Likewise, if one wound is located on the front of a limb or the torso and a second wound is located on the reverse side, it may not be possible to bridge the wound dressings. In essence, the geometries and locations of the wounds may hinder the bridge from delivering satisfactory instillation therapy to either of the wounds.

[0008] Furthermore, a clinician may wish to deliver negative pressure wound therapy to a patient with a large wound. Clinical practice includes using multiple therapy units in such situations. In such a case, unsynchronized therapy can hinder accurate and consist negative pressure delivery to the wound. For example, a leak or blockage condition in one unit may compromise negative pressure control in other units.

[0009] There is a need to provide negative-pressure wound therapy (NPWT) systems and instillation therapy systems in situations where it is not possible to bridge two wounds with multiple wound dressings or to treat a single large wound with multiple wound dressings.

BRIEF SUMMARY

[0010] New and useful systems, apparatuses, and methods for instilling fluid to a tissue site in a negative-pressure therapy environment are set forth in the appended claims. Illustrative embodiments are also provided to enable a person skilled in the art to make and use the claimed subject matter. Some embodiments are illustrative of an apparatus or system for delivering negative -pressure and therapeutic solution of fluids to a tissue site, which can be used in conjunction with sensing properties of wound exudates extracted from a tissue site. For example, an apparatus may include a pH sensor, a humidity sensor, a temperature sensor and a pressure sensor embodied on a single pad proximate the tissue site to provide data indicative of acidity, humidity, temperature and pressure. Such apparatus may further comprise an algorithm for processing such data for detecting leakage and blockage as well as providing information relating to the progression of healing of wounds at the tissue site. [0011] It is an object of the disclosure to provide a system for providing negative pressure therapy at a tissue site. The system comprises: i) a primary therapy controller; ii) a first dressing interface configured to be controlled by the primary therapy controller and to provide at least one of first negative pressure therapy or first instillation therapy at the tissue site; iii) a secondary therapy controller configured to be controlled by the primary therapy controller; and iv) a second dressing interface configured to be controlled by the secondary therapy controller and to provide at least one of second negative pressure therapy or second instillation therapy at the tissue site.

[0012] In one embodiment, the primary therapy controller is configured to receive primary user inputs from an operator of the system, the primary user inputs including configurable parameters operable to configure the first dressing interface to provide the at least one of first negative pressure therapy or first instillation therapy at the tissue site.

[0013] In another embodiment, the primary user inputs further include timing information operable to configure the first dressing interface to initiate and to halt the at least one of first negative pressure therapy or first instillation therapy at the tissue site.

[0014] In still another embodiment, the primary therapy controller is configured to receive secondary user inputs from an operator of the system, the secondary user inputs including configurable parameters operable to configure the second dressing interface to provide the at least one of second negative pressure therapy or second instillation therapy at the tissue site.

[0015] In yet another embodiment, the secondary user inputs further include timing information operable to configure the second dressing interface to initiate and to halt the at least one of second negative pressure therapy or second instillation therapy at the tissue site.

[0016] In a further embodiment, the primary therapy controller transmits the secondary user inputs to the secondary therapy controller.

[0017] In a still further embodiment, the primary therapy controller and secondary therapy controller are configured to establish a wireless communication link to enable the primary therapy controller to transmit the secondary user inputs to the secondary therapy controller.

[0018] It is an object of the disclosure to provide a method for providing therapy at a tissue site. The method comprises: i) in a primary therapy controller, receiving from an operator primary user inputs, wherein the primary user inputs include configurable parameters operable to configure a first dressing interface to provide at least one of first negative pressure therapy or first instillation therapy at the tissue site; ii) in the primary therapy controller, receiving from the operator secondary user inputs, wherein the secondary user inputs include configurable parameters operable to configure a second dressing interface to provide at least one of second negative pressure therapy or second instillation therapy at the tissue site; iii) transmitting the secondary user inputs from the primary therapy controller to a second therapy controller that is controlled by the primary therapy controller; iv) in the first dressing interface, applying the at least one of first negative pressure therapy or first instillation therapy at the tissue site under the control of the primary therapy controller; and v) in the second dressing interface, applying the at least one of second negative pressure therapy or second instillation therapy at the tissue site under the control of the secondary therapy controller.

[0019] Objectives, advantages, and a preferred mode of making and using the claimed subject matter may be understood best by reference to the accompanying drawings in conjunction with the following detailed description of illustrative embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 is a functional block diagram of an example embodiment of a therapy system that can provide negative -pressure and instillation in accordance with this specification;

[0021] Figure 2A is a graph illustrating an illustrative embodiment of pressure control modes for the negative-pressure and instillation therapy system of Figure 1 wherein the x-axis represents time in minutes (min) and/or seconds(sec) and the y-axis represents pressure generated by a pump in Torr (mmHg) that varies with time in a continuous pressure mode and an intermittent pressure mode that may be used for applying negative pressure in the therapy system;

[0022] Figure 2B is a graph illustrating an illustrative embodiment of another pressure control mode for the negative-pressure and instillation therapy system of Figure 1 wherein the x-axis represents time in minutes (min) and/or seconds(sec) and the y-axis represents pressure generated by a pump in Torr (mmHg) that varies with time in a dynamic pressure mode that may be used for applying negative pressure in the therapy system;

[0023] Figure 3 is a schematic block diagram showing an illustrative embodiment of a therapy method for providing negative-pressure and instillation therapy for delivering treatment solutions to a dressing at a tissue site;

[0024] Figure 4 is a sectional side view of a dressing interface comprising a housing and a wall disposed within the housing and forming a therapy cavity including sensors and a component cavity including electrical devices that may be associated with some example embodiments of the therapy system of Figure 1;

[0025] Figure 5A is a perspective top view of the dressing interface of Figure 4, Figure 5B is a side view of the dressing interface of Figure 4 disposed on a tissue site, and Figure 5C is an end view of the dressing interface of Figure 4 disposed on the tissue site;

[0026] Figure 6A is an assembly view of the dressing interface of Figure 4 comprising components of the housing and a first example embodiment of a sensor assembly including the wall, the sensors, and the electrical devices;

[0027] Figure 6B is a system block diagram of the sensors and electrical devices comprising the sensor assembly of Figure 6A;

[0028] Figures 7A, 7B and 7C are a top view, side view, and bottom view, respectively, of the sensor assembly of Figure 6;

[0029] Figure 7D is a perspective top view of the sensor assembly of the sensor assembly of Figure 6 including one example embodiment of a pH sensor; [0030] Figure 8A is a perspective bottom view of the dressing interface of Figure 4, and Figure 8B is a bottom view of the dressing interface of Figure 4;

[0031] Figure 9A is a top view of a first embodiment of a pH sensor that may be used with the sensor assembly of Figure 7D, and Figure 9B is a top view of a second embodiment of a pH sensor that may be used with the sensor assembly of Figure 7D;

[0032] Figure 10 is a flow chart illustrating a method for treating a tissue site utilizing the dressing interface of Figure 4 for applying negative -pressure therapy with fluid instillation and sensing properties of wound exudates extracted from the tissue site;

[0033] Figure 11 is a schematic block diagram illustrating a negative pressure control algorithm utilized within the tissue treatment method of Figure 10 including the detection of dressing flow characteristics within the system and the assessment of sensor properties;

[0034] Figure 12 is a block diagram of a user interface illustrating alerts and alarms associated with the dressing flow characteristics of Figure 11;

[0035] Figure 13A is a flow chart illustrating a wound pressure control method configured to operate in the negative pressure control algorithm of Figure 11;

[0036] Figure 13B is a flow chart illustrating a method for detecting blockages and fluid leaks as two of the dressing flow characteristics of Figure 11;

[0037] Figure 13C is a flow chart illustrating a method for detecting air leaks and desiccation as two of the dressing flow characteristics of Figure 11, and for logging and assessing the sensing properties;

[0038] Figure 14 is a graph illustrating data associated with the detection of blockages based on the assessment of humidity data and wound pressure over time generated by the negative pressure control algorithm of Figure 11 ;

[0039] Figure 15 is a graph illustrating data associated with the detection of fluid leaks based on the assessment of humidity data and wound pressure data over time generated by the negative pressure control algorithm of Figure 11 ;

[0040] Figure 16 is a graph illustrating data associated with the detection of air leaks based on the assessment of humidity data, wound pressure data, and pump pressure data over time generated by the negative pressure control algorithm of Figure 11;

[0041] Figure 17 is a graph illustrating data associated with the detection of desiccation conditions based on the assessment of humidity data over time generated by the negative pressure control algorithm of Figure 11 ;

[0042] Figure 18 is a schematic block diagram illustrating a fluid instillation control algorithm utilized within the tissue treatment method of Figure 10 including the detection of dressing flow characteristics within the system and the assessment of sensor properties and dispensed volume;

[0043] Figure 19A is a flow chart illustrating an automated fill assist control method configured to operate in the fluid instillation control algorithm of Figure 18; [0044] Figure 19B is a flow chart illustrating a method for detecting blockages and fluid leaks as two of the dressing flow characteristics of Figure 18; and

[0045] Figure 20 is a graph illustrating an instillation response curve including data associated with the relative humidity percentage of a dressing in response to the fluid instillation control algorithm of Figure 18.

[0046] Figure 21 is a block diagram of a wireless module architecture of the sensor assembly and therapy system according to an exemplary embodiment of the disclosure.

[0047] Figure 22 is a first wireless network topology for controlling the therapy system according to an exemplary embodiment of the disclosure.

[0048] Figure 23 is a second wireless network topology for controlling the therapy system according to an exemplary embodiment of the disclosure.

[0049] Figure 24 is a third wireless network topology for controlling the therapy system according to an exemplary embodiment of the disclosure.

[0050] Figure 25 is a method for wirelessly controlling the dressing interface and the therapy system according to an exemplary embodiment of the disclosure.

[0051] Figure 26 is a method for wirelessly controlling the dressing interface and the therapy system according to an exemplary embodiment of the disclosure.

[0052] Figure 27 is a block diagram of a wireless therapy controller according to an exemplary embodiment of the disclosure.

[0053] Figure 28 is a method for wirelessly controlling the dressing interface and the therapy system according to an exemplary embodiment of the disclosure.

[0054] Figure 29 is a functional block diagram of an example embodiment of multiple therapy systems that can provide coordinated negative-pressure and instillation to multiple wounds in accordance with this specification.

[0055] Figure 30 is a functional block diagram of an example embodiment of multiple therapy systems that can provide coordinated negative-pressure and instillation to a large wound in accordance with this specification.

[0056] Figure 31 is a method for providing coordinated negative-pressure and instillation using multiple therapy systems according to an exemplary embodiment of the disclosure.

DESCRIPTION OF EXAMPLE EMBODIMENTS

[0057] The following description of example embodiments provides information that enables a person skilled in the art to make and use the subject matter set forth in the appended claims, but may omit certain details already well-known in the art. The following detailed description is, therefore, to be taken as illustrative and not limiting.

[0058] The example embodiments may also be described herein with reference to spatial relationships between various elements or to the spatial orientation of various elements depicted in the attached drawings. In general, such relationships or orientation assume a frame of reference consistent with or relative to a patient in a position to receive treatment. However, as should be recognized by those skilled in the art, this frame of reference is merely a descriptive expedient rather than a strict prescription.

[0059] The term “tissue site” in this context broadly refers to a wound, defect, or other treatment target located on or within tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. A wound may include chronic, acute, traumatic, subacute, and dehisced wounds, partial thickness bums, ulcers (such as diabetic, pressure, or venous insufficiency ulcers), flaps, and grafts, for example. The term “tissue site” may also refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it may be desirable to add or promote the growth of additional tissue. For example, negative pressure may be applied to a tissue site to grow additional tissue that may be harvested and transplanted.

[0060] The present technology also provides negative pressure therapy devices and systems, and methods of treatment using such systems with antimicrobial solutions. Figure 1 is a simplified functional block diagram of an example embodiment of a therapy system 100 that can provide negative- pressure therapy with instillation of treatment solutions in accordance with this specification. The therapy system 100 may include a negative-pressure supply, and may include or be configured to be coupled to a distribution component, such as a dressing. In general, a distribution component may refer to any complementary or ancillary component configured to be fluidly coupled to a negative-pressure supply between a negative-pressure supply and a tissue site. A distribution component is preferably detachable, and may be disposable, reusable, or recyclable. For example, a dressing 102 is illustrative of a distribution component that may be coupled to a negative-pressure source and other components. The therapy system 100 may be packaged as a single, integrated unit such as a therapy system including all of the components shown in Figure 1 that are fluidly coupled to the dressing 102. The therapy system may be, for example, a V.A.C. Ulta™ System available from Kinetic Concepts, Inc. of San Antonio, Texas.

[0061] The dressing 102 may be fluidly coupled to a negative-pressure source 104. A dressing may include a cover, a tissue interface, or both in some embodiments. The dressing 102, for example, may include a cover 106, a dressing interface 107, and a tissue interface 108. A computer or a controller device, such as a controller 110, may also be coupled to the negative-pressure source 104. In some embodiments, the cover 106 may be configured to cover the tissue interface 108 and the tissue site, and may be adapted to seal the tissue interface and create a therapeutic environment proximate to a tissue site for maintaining a negative pressure at the tissue site. In some embodiments, the dressing interface 107 may be configured to fluidly couple the negative-pressure source 104 to the therapeutic environment of the dressing. The therapy system 100 may optionally include a fluid container, such as a container 112, fluidly coupled to the dressing 102 and to the negative-pressure source 104. [0062] The therapy system 100 may also include a source of instillation solution, such as a solution source 114. A distribution component may be fluidly coupled to a fluid path between a solution source and a tissue site in some embodiments. For example, an instillation pump 116 may be coupled to the solution source 114, as illustrated in the example embodiment of Figure 1. The instillation pump 116 may also be fluidly coupled to the negative-pressure source 104 such as, for example, by a fluid conductor 119. In some embodiments, the instillation pump 116 may be directly coupled to the negative-pressure source 104, as illustrated in Figure 1, but may be indirectly coupled to the negative- pressure source 104 through other distribution components in some embodiments. For example, in some embodiments, the instillation pump 116 may be fluidly coupled to the negative-pressure source 104 through the dressing 102. In some embodiments, the instillation pump 116 and the negative- pressure source 104 may be fluidly coupled to two different locations on the tissue interface 108 by two different dressing interfaces. For example, the negative -pressure source 104 may be fluidly coupled to the dressing interface 107 while the instillation pump 116 may be fluidly to the coupled to dressing interface 107 or a second dressing interface 117. In some other embodiments, the instillation pump 116 and the negative-pressure source 104 may be fluidly coupled to two different tissue interfaces by two different dressing interfaces, one dressing interface for each tissue interface (not shown).

[0063] The therapy system 100 also may include sensors to measure operating parameters and provide feedback signals to the controller 110 indicative of the operating parameters properties of fluids extracted from a tissue site. As illustrated in Figure 1, for example, the therapy system 100 may include a pressure sensor 120, an electric sensor 124, or both, coupled to the controller 110. The pressure sensor 120 may be fluidly coupled or configured to be fluidly coupled to a distribution component such as, for example, the negative-pressure source 104 either directly or indirectly through the container 112. The pressure sensor 120 may be configured to measure pressure being generated by the negative-pressure source 104, i.e., the pump pressure (PP). The electric sensor 124 also may be coupled to the negative- pressure source 104 to measure the pump pressure (PP). In some example embodiments, the electric sensor 124 may be fluidly coupled proximate the output of the negative-pressure source 104 to directly measure the pump pressure (PP). In other example embodiments, the electric sensor 124 may be electrically coupled to the negative -pressure source 104 to measure the changes in the current in order to determine the pump pressure (PP).

[0064] Distribution components may be fluidly coupled to each other to provide a distribution system for transferring fluids (i.e., liquid and/or gas). For example, a distribution system may include various combinations of fluid conductors and fittings to facilitate fluid coupling. A fluid conductor generally includes any structure with one or more lumina adapted to convey a fluid between two ends, such as a tube, pipe, hose, or conduit. Typically, a fluid conductor is an elongated, cylindrical structure with some flexibility, but the geometry and rigidity may vary. Some fluid conductors may be molded into or otherwise integrally combined with other components. A fitting can be used to mechanically and fluidly couple components to each other. For example, a fitting may comprise a projection and an aperture. The projection may be configured to be inserted into a fluid conductor so that the aperture aligns with a lumen of the fluid conductor. A valve is a type of fitting that can be used to control fluid flow. For example, a check valve can be used to substantially prevent return flow. A port is another example of a fitting. A port may also have a projection, which may be threaded, flared, tapered, barbed, or otherwise configured to provide a fluid seal when coupled to a component.

[0065] In some embodiments, distribution components may also be coupled by virtue of physical proximity, being integral to a single structure, or being formed from the same piece of material. Coupling may also include mechanical, thermal, electrical, or chemical coupling (such as a chemical bond) in some contexts. For example, a tube may mechanically and fluidly couple the dressing 102 to the container 112 in some embodiments. In general, components of the therapy system 100 may be coupled directly or indirectly. For example, the negative-pressure source 104 may be directly coupled to the controller 110, and may be indirectly coupled to the dressing interface 107 through the container 112 by conduit 126 and conduit 130. The pressure sensor 120 may be fluidly coupled to the dressing 102 directly (not shown) or indirectly by conduit 121 and conduit 122. Additionally, the instillation pump 116 may be coupled indirectly to the dressing interface 107 through the solution source 114 and the instillation regulator 115 by fluid conductors 132, 134 and 138. Alternatively, the instillation pump 116 may be coupled indirectly to the second dressing interface 117 through the solution source 114 and the instillation regulator 115 by fluid conductors 132, 134 and 139.

[0066] The fluid mechanics of using a negative-pressure source to reduce pressure in another component or location, such as within a sealed therapeutic environment, can be mathematically complex. However, the basic principles of fluid mechanics applicable to negative-pressure therapy and instillation are generally well-known to those skilled in the art, and the process of reducing pressure may be described illustratively herein as “delivering,” “distributing,” or “generating” negative pressure, for example.

[0067] In general, exudates and other fluids flow toward lower pressure along a fluid path. Thus, the term “downstream” typically implies something in a fluid path relatively closer to a source of negative pressure or further away from a source of positive pressure. Conversely, the term “upstream” implies something relatively further away from a source of negative pressure or closer to a source of positive pressure. Similarly, it may be convenient to describe certain features in terms of fluid “inlet” or “outlet” in such a frame of reference. This orientation is generally presumed for purposes of describing various features and components herein. However, the fluid path may also be reversed in some applications (such as by substituting a positive-pressure source for a negative-pressure source) and this descriptive convention should not be construed as a limiting convention.

[0068] “Negative pressure” generally refers to a pressure less than a local ambient pressure, such as the ambient pressure in a local environment external to a sealed therapeutic environment provided by the dressing 102. In many cases, the local ambient pressure may also be the atmospheric pressure at which a tissue site is located. Alternatively, the pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Similarly, references to increases in negative pressure typically refer to a decrease in absolute pressure, while decreases in negative pressure typically refer to an increase in absolute pressure. While the amount and nature of negative pressure applied to a tissue site may vary according to therapeutic requirements, the pressure is generally a low vacuum, also commonly referred to as a rough vacuum, between -5 mm Hg (-667 Pa) and -500 mm Hg (-66.7 kPa). Common therapeutic ranges are between -75 mm Hg (-9.9 kPa) and -300 mm Hg (-39.9 kPa).

[0069] A negative-pressure supply, such as the negative-pressure source 104, may be a reservoir of air at a negative pressure, or may be a manual or electrically-powered device that can reduce the pressure in a sealed volume, such as a vacuum pump, a suction pump, a wall suction port available at many healthcare facilities, or a micro-pump, for example. A negative-pressure supply may be housed within or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate therapy. For example, in some embodiments, the negative-pressure source 104 may be combined with the controller 110 and other components into a therapy unit. A negative-pressure supply may also have one or more supply ports configured to facilitate coupling and de-coupling the negative-pressure supply to one or more distribution components.

[0070] The tissue interface 108 can be generally adapted to contact a tissue site. The tissue interface 108 may be partially or fully in contact with the tissue site. If the tissue site is a wound, for example, the tissue interface 108 may partially or completely fill the wound, or may be placed over the wound. The tissue interface 108 may take many forms, and may have many sizes, shapes, or thicknesses depending on a variety of factors, such as the type of treatment being implemented or the nature and size of a tissue site. For example, the size and shape of the tissue interface 108 may be adapted to the contours of deep and irregular shaped tissue sites. Moreover, any or all of the surfaces of the tissue interface 108 may have projections or an uneven, course, or jagged profile that can induce strains and stresses on a tissue site, which can promote granulation at the tissue site.

[0071] In some embodiments, the tissue interface 108 may be a manifold such as manifold 408 shown in Figure 4. A "manifold" in this context generally includes any substance or structure providing a plurality of pathways adapted to collect or distribute fluid across a tissue site under pressure. For example, a manifold may be adapted to receive negative pressure from a source and distribute negative pressure through multiple apertures across a tissue site, which may have the effect of collecting fluid from across a tissue site and drawing the fluid toward the source. In some embodiments, the fluid path may be reversed or a secondary fluid path may be provided to facilitate delivering fluid across a tissue site.

[0072] In some illustrative embodiments, the pathways of a manifold may be interconnected to improve distribution or collection of fluids across a tissue site. In some illustrative embodiments, a manifold may be a porous foam material having interconnected cells or pores. For example, cellular foam, open-cell foam, reticulated foam, porous tissue collections, and other porous material such as gauze or felted mat generally include pores, edges, and/or walls adapted to form interconnected fluid channels. Liquids, gels, and other foams may also include or be cured to include apertures and fluid pathways. In some embodiments, a manifold may additionally or alternatively comprise projections that form interconnected fluid pathways. For example, a manifold may be molded to provide surface projections that define interconnected fluid pathways.

[0073] The average pore size of a foam manifold may vary according to needs of a prescribed therapy. For example, in some embodiments, the tissue interface 108 may be a foam manifold having pore sizes in a range of 400-600 microns. The tensile strength of the tissue interface 108 may also vary according to needs of a prescribed therapy. For example, the tensile strength of a foam may be increased for instillation of topical treatment solutions. In one non-limiting example, the tissue interface 108 may be an open-cell, reticulated polyurethane foam such as GranuFoam^® dressing or VeraFlo^® foam, both available from Kinetic Concepts, Inc. of San Antonio, Texas.

[0074] The tissue interface 108 may be either hydrophobic or hydrophilic. In an example in which the tissue interface 108 may be hydrophilic, the tissue interface 108 may also wick fluid away from a tissue site, while continuing to distribute negative pressure to the tissue site. The wicking properties of the tissue interface 108 may draw fluid away from a tissue site by capillary flow or other wicking mechanisms. An example of a hydrophilic foam is a polyvinyl alcohol, open-cell foam such as V.A.C. WhiteFoam^® dressing available from Kinetic Concepts, Inc. of San Antonio, Texas. Other hydrophilic foams may include those made from polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.

[0075] The tissue interface 108 may further promote granulation at a tissue site when pressure within the sealed therapeutic environment is reduced. For example, any or all of the surfaces of the tissue interface 108 may have an uneven, coarse, or jagged profile that can induce microstrains and stresses at a tissue site if negative pressure is applied through the tissue interface 108.

[0076] In some embodiments, the tissue interface 108 may be constructed from bioresorbable materials. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include without limitation polycarbonates, polyfumarates, and capralactones. The tissue interface 108 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with the tissue interface 108 to promote cell -growth. A scaffold is generally a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials.

[0077] In some embodiments, the cover 106 may provide a bacterial barrier and protection from physical trauma. The cover 106 may also be constructed from a material that can reduce evaporative losses and provide a fluid seal between two components or two environments, such as between a therapeutic environment and a local external environment. The cover 106 may be, for example, an elastomeric film or membrane that can provide a seal adequate to maintain a negative pressure at a tissue site for a given negative-pressure source. The cover 106 may have a high moisture- vapor transmission rate (MVTR) in some applications. For example, the MVTR may be at least 300 g/m^A2 per twenty-four hours in some embodiments. In some example embodiments, the cover 106 may be a polymer drape, such as a polyurethane film, that is permeable to water vapor but impermeable to liquid. Such drapes typically have a thickness in the range of 25-50 microns. For permeable materials, the permeability generally should be low enough that a desired negative pressure may be maintained. In some embodiments, the cover may be a drape such as drape 406 shown in Figure 4.

[0078] An attachment device may be used to attach the cover 106 to an attachment surface, such as undamaged epidermis, a gasket, or another cover. The attachment device may take many forms. For example, an attachment device may be a medically-acceptable, pressure-sensitive adhesive that extends about a periphery, a portion, or an entire sealing member. In some embodiments, for example, some or all of the cover 106 may be coated with an acrylic adhesive having a coating weight between 25-65 grams per square meter (g.s.m.). Thicker adhesives, or combinations of adhesives, may be applied in some embodiments to improve the seal and reduce leaks. Other example embodiments of an attachment device may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, or organogel.

[0079] In some embodiments, the dressing interface 107 may facilitate coupling the negative- pressure source 104 to the dressing 102. The negative pressure provided by the negative-pressure source 104 may be delivered through the conduit 130 to a negative -pressure interface, which may include an elbow portion. In one illustrative embodiment, the negative-pressure interface may be a T.R.A.C.^® Pad or Sensa T.R.A.C.^® Pad available from KCI of San Antonio, Texas. The negative- pressure interface enables the negative pressure to be delivered through the cover 106 and to the tissue interface 108 and the tissue site. In this illustrative, non-limiting embodiment, the elbow portion may extend through the cover 106 to the tissue interface 108, but numerous arrangements are possible.

[0080] A controller, such as the controller 110, may be a microprocessor or computer programmed to operate one or more components of the therapy system 100, such as the negative- pressure source 104. In some embodiments, for example, the controller 110 may be a microcontroller, which generally comprises an integrated circuit containing a processor core and a memory programmed to directly or indirectly control one or more operating parameters of the therapy system 100. Operating parameters may include the power applied to the negative-pressure source 104, the pressure generated by the negative-pressure source 104, or the pressure distributed to the tissue interface 108, for example. The controller 110 is also preferably configured to receive one or more input signals, such as a feedback signal, and programmed to modify one or more operating parameters based on the input signals.

[0081] Sensors, such as the pressure sensor 120 or the electric sensor 124, are generally known in the art as any apparatus operable to detect or measure a physical phenomenon or property, and generally provide a signal indicative of the phenomenon or property that is detected or measured. For example, the pressure sensor 120 and the electric sensor 124 may be configured to measure one or more operating parameters of the therapy system 100. In some embodiments, the pressure sensor 120 may be a transducer configured to measure pressure in a pneumatic pathway and convert the measurement to a signal indicative of the pressure measured. In some embodiments, for example, the pressure sensor 120 may be a piezoresistive strain gauge. The electric sensor 124 may optionally measure operating parameters of the negative-pressure source 104, such as the voltage or current, in some embodiments. Preferably, the signals from the pressure sensor 120 and the electric sensor 124 are suitable as an input signal to the controller 110, but some signal conditioning may be appropriate in some embodiments. For example, the signal may need to be filtered or amplified before it can be processed by the controller 110. Typically, the signal is an electrical signal that is transmitted and/or received on by wire or wireless means, but may be represented in other forms, such as an optical signal.

[0082] The solution source 114 is representative of a container, canister, pouch, bag, or other storage component, which can provide a solution for instillation therapy. Compositions of solutions may vary according to a prescribed therapy, but examples of solutions that may be suitable for some prescriptions include hypochlorite-based solutions, silver nitrate (0.5%), sulfur-based solutions, biguanides, cationic solutions, and isotonic solutions. Examples of such other therapeutic solutions that may be suitable for some prescriptions include hypochlorite -based solutions, silver nitrate (0.5%), sulfur-based solutions, biguanides, cationic solutions, and isotonic solutions. In one illustrative embodiment, the solution source 114 may include a storage component for the solution and a separate cassette for holding the storage component and delivering the solution to the tissue site 150, such as a V.A.C. VeraLink™ Cassette available from Kinetic Concepts, Inc. of San Antonio, Texas.

[0083] The container 112 may also be representative of a container, canister, pouch, or other storage component, which can be used to collect and manage exudates and other fluids withdrawn from a tissue site. In many environments, a rigid container such as, for example, a container 162, may be preferred or required for collecting, storing, and disposing of fluids. In other environments, fluids may be properly disposed of without rigid container storage, and a re-usable container could reduce waste and costs associated with negative-pressure therapy. In some embodiments, the container 112 may comprise a canister having a collection chamber, a first inlet fluidly coupled to the collection chamber and a first outlet fluidly coupled to the collection chamber and adapted to receive negative pressure from a source of negative pressure. In some embodiments, a first fluid conductor may comprise a first member such as, for example, the conduit 130 fluidly coupled between the first inlet and the tissue interface 108 by the negative-pressure interface described above, and a second member such as, for example, the conduit 126 fluidly coupled between the first outlet and a source of negative pressure whereby the first conductor is adapted to provide negative pressure within the collection chamber to the tissue site. [0084] The therapy system 100 may also comprise a flow regulator such as, for example, a regulator 118 fluidly coupled to a source of ambient air to provide a controlled or managed flow of ambient air to the sealed therapeutic environment provided by the dressing 102 and ultimately the tissue site. In some embodiments, the regulator 118 may control the flow of ambient fluid to purge fluids and exudates from the sealed therapeutic environment. In some embodiments, the regulator 118 may be fluidly coupled by a fluid conductor or vent conduit 135 through the dressing interface 107 to the tissue interface 108. The regulator 118 may be configured to fluidly couple the tissue interface 108 to a source of ambient air as indicated by a dashed arrow. In some embodiments, the regulator 118 may be disposed within the therapy system 100 rather than being proximate to the dressing 102 so that the air flowing through the regulator 118 is less susceptible to accidental blockage during use. In such embodiments, the regulator 118 may be positioned proximate the container 112 and/or proximate a source of ambient air where the regulator 118 is less likely to be blocked during usage.

[0085] In operation, the tissue interface 108 may be placed within, over, on, or otherwise proximate a tissue site, such as tissue site 150. The cover 106 may be placed over the tissue interface 108 and sealed to an attachment surface near the tissue site 150. For example, the cover 106 may be sealed to undamaged epidermis peripheral to a tissue site. Thus, the dressing 102 can provide a sealed therapeutic environment proximate to a tissue site, substantially isolated from the external environment, and the negative-pressure source 104 can reduce the pressure in the sealed therapeutic environment. Negative pressure applied across the tissue site through the tissue interface 108 in the sealed therapeutic environment can induce macrostrain and microstrain in the tissue site, as well as remove exudates and other fluids from the tissue site, which can be collected in container 112.

[0086] In one embodiment, the controller 110 may receive and process data, such as data related to the pressure distributed to the tissue interface 108 from the pressure sensor 120. The controller 110 may also control the operation of one or more components of therapy system 100 to manage the pressure distributed to the tissue interface 108 for application to the wound at the tissue site 150, which may also be referred to as the wound pressure (WP). In one embodiment, controller 110 may include an input for receiving a desired target pressure (TP) set by a clinician or other user and may be programmed for processing data relating to the setting and inputting of the target pressure (TP) to be applied to the tissue site 150. In one example embodiment, the target pressure (TP) may be a fixed pressure value determined by a user/caregiver as the reduced pressure target desired for therapy at the tissue site 150 and then provided as input to the controller 110. The user may be a nurse or a doctor or other approved clinician who prescribes the desired negative pressure to which the tissue site 150 should be applied. The desired negative pressure may vary from tissue site to tissue site based on the type of tissue forming the tissue site 150, the type of injury or wound (if any), the medical condition of the patient, and the preference of the attending physician. After selecting the desired target pressure (TP), the negative-pressure source 104 is controlled to achieve the target pressure (TP) desired for application to the tissue site 150. [0087] Referring more specifically to Figure 2A, a graph illustrating an illustrative embodiment of pressure control modes 200 that may be used for the negative-pressure and instillation therapy system of Figure 1 is shown wherein the x-axis represents time in minutes (min) and/or seconds (sec) and the y-axis represents pressure generated by a pump in Torr (mmHg) that varies with time in a continuous pressure mode and an intermittent pressure mode that may be used for applying negative pressure in the therapy system. The target pressure (TP) may be set by the user in a continuous pressure mode as indicated by solid line 201 and dotted line 202 wherein the wound pressure (WP) is applied to the tissue site 150 until the user deactivates the negative-pressure source 104. The target pressure (TP) may also be set by the user in an intermittent pressure mode as indicated by solid lines 201, 203 and 205 wherein the wound pressure (WP) is cycled between the target pressure (TP) and atmospheric pressure. For example, the target pressure (TP) may be set by the user at a value of 125 mmHg for a specified period of time (e.g., 5 min) followed by the therapy being turned off for a specified period of time (e.g., 2 min) as indicated by the gap between the solid lines 203 and 205 by venting the tissue site 150 to the atmosphere, and then repeating the cycle by turning the therapy back on as indicated by solid line 205 which consequently forms a square wave pattern between the target pressure (TP) level and atmospheric pressure. In some embodiments, the ratio of the “on-time” to the “off-time” or the total “cycle time” may be referred to as a pump duty cycle (PD).

[0088] In some example embodiments, the decrease in the wound pressure (WP) at the tissue site 150 from ambient pressure to the target pressure (TP) is not instantaneous, but rather gradual depending on the type of therapy equipment and dressing being used for the particular therapy treatment. For example, the negative-pressure source 104 and the dressing 102 may have an initial rise time as indicated by the dashed line 207 that may vary depending on the type of dressing and therapy equipment being used. For example, the initial rise time for one therapy system may be in the range between about 20-30 mmHg/second or, more specifically, equal to about 25 mmHg/second, and in the range between about 5-10 mmHg/second for another therapy system. When the therapy system 100 is operating in the intermittent mode, the repeating rise time as indicated by the solid line 205 may be a value substantially equal to the initial rise time as indicated by the dashed line 207.

[0089] The target pressure may also be a variable target pressure (VTP) controlled or determined by controller 110 that varies in a dynamic pressure mode. For example, the variable target pressure (VTP) may vary between a maximum and minimum pressure value that may be set as an input determined by a user as the range of negative pressures desired for therapy at the tissue site 150. The variable target pressure (VTP) may also be processed and controlled by controller 110 that varies the target pressure (TP) according to a predetermined waveform such as, for example, a sine waveform or a saw-tooth waveform or a triangular waveform, that may be set as an input by a user as the predetermined or time-varying reduced pressures desired for therapy at the tissue site 150.

[0090] Referring more specifically to Figure 2B, a graph illustrating an illustrative embodiment of another pressure control mode 210 for the negative-pressure and instillation therapy system of Figure 1 is shown wherein the x-axis represents time in minutes (min) and/or seconds (sec) and the y-axis represents pressure generated by a pump in Torr (mmHg) that varies with time in a dynamic pressure mode that may be used for applying negative pressure in the therapy system. For example, the variable target pressure (VTP) may be a reduced pressure that provides an effective treatment by applying reduced pressure to tissue site 150 in the form of a triangular waveform varying between a minimum and maximum pressure of 50-125 mmHg with a rise time 212 set at a rate of +25 mmHg/minute and a descent time 211 set at -25 mmHg/minute, respectively. In another embodiment of the therapy system 100, the variable target pressure (VTP) may be a reduced pressure that applies reduced pressure to tissue site 150 in the form of a triangular waveform varying between 25-125 mmHg with a rise time 212 set at a rate of +30 mmHg/min and a descent time 211 set at -30 mmHg/min. Again, the type of system and tissue site determines the type of reduced pressure therapy to be used.

[0091] Figure 3 is a flow chart illustrating an illustrative embodiment of a therapy method 300 that may be used for providing negative-pressure and instillation therapy for delivering an antimicrobial solution or other treatment solution to a dressing at a tissue site. In one embodiment, the controller 110 receives and processes data, such as data related to fluids provided to the tissue interface. Such data may include the type of instillation solution prescribed by a clinician, the volume of fluid or solution to be instilled to the tissue site (“fill volume”), and the amount of time needed to soak the tissue interface (“soak time”) before applying a negative pressure to the tissue site. The fill volume may be, for example, between 10 and 500 mL, and the soak time may be between one second to 30 minutes. The controller 110 may also control the operation of one or more components of the therapy system 100 to manage the fluids distributed from the solution source 114 for instillation to the tissue site 150 for application to the wound as described in more detail above. In one embodiment, fluid may be instilled to the tissue site 150 by applying a negative pressure from the negative -pressure source 104 to reduce the pressure at the tissue site 150 to draw the instillation fluid into the dressing 102 as indicated at 302. In another embodiment, fluid may be instilled to the tissue site 150 by applying a positive pressure from the negative-pressure source 104 (not shown) or the instillation pump 116 to force the instillation fluid from the solution source 114 to the tissue interface 108 as indicated at 304. In yet another embodiment, fluid may be instilled to the tissue site 150 by elevating the solution source 114 to height sufficient to force the instillation fluid into the tissue interface 108 by the force of gravity as indicated at 306. Thus, the therapy method 300 includes instilling fluid into the tissue interface 108 by either drawing or forcing the fluid into the tissue interface 108 as indicated at 310.

[0092] The therapy method 300 may control the fluid dynamics of applying the fluid solution to the tissue interface 108 at 312 by providing a continuous flow of fluid at 314 or an intermittent flow of fluid for soaking the tissue interface 108 at 316. The therapy method 300 may include the application of negative pressure to the tissue interface 108 to provide either the continuous flow or intermittent soaking flow of fluid at 320. The application of negative pressure may be implemented to provide a continuous pressure mode of operation at 322 as described above to achieve a continuous flow rate of instillation fluid through the tissue interface 108 or a dynamic pressure mode of operation at 324 as described above to vary the flow rate of instillation fluid through the tissue interface 108. Alternatively, the application of negative pressure may be implemented to provide an intermittent mode of operation at 326 as described above to allow instillation fluid to soak into the tissue interface 108 as described above. In the intermittent mode, a specific fill volume and the soak time may be provided depending, for example, on the type of wound being treated and the type of dressing 102 being utilized to treat the wound. After or during instillation of fluid into the tissue interface 108 has been completed, the therapy method 300 may be utilized using any one of the three modes of operation at 330 as described above. The controller 110 may be utilized to select any one of these three modes of operation and the duration of the negative pressure therapy as described above before commencing another instillation cycle at 340 by instilling more fluid at 310.

[0093] As discussed above, the tissue site 150 may include, without limitation, any irregularity with a tissue, such as an open wound, surgical incision, or diseased tissue. The therapy system 100 is presented in the context of a tissue site that includes a wound that may extend through the epidermis and the dermis, and may reach into the hypodermis or subcutaneous tissue. The therapy system 100 may be used to treat a wound of any depth, as well as many different types of wounds including open wounds, incisions, or other tissue sites. The tissue site 150 may be the bodily tissue of any human, animal, or other organism, including bone tissue, adipose tissue, muscle tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, ligaments, or any other tissue. Treatment of the tissue site 150 may include removal of fluids originating from the tissue site 150, such as exudates or ascites, or fluids instilled into the dressing to cleanse or treat the tissue site 150, such as antimicrobial solutions.

[0094] As indicated above, the therapy system 100 may be packaged as a single, integrated unit such as a therapy system including all of the components shown in Figure 1 that are fluidly coupled to the dressing 102. In some embodiments, an integrated therapy unit may include the negative-pressure source 104, the controller 110, the pressure sensor 120, and the container 112 which may be fluidly coupled to the dressing interface 107. In this therapy unit, the negative-pressure source 104 is indirectly coupled to the dressing interface 107 through the container 112 by conduit 126 and conduit 130, and the pressure sensor 120 is indirectly coupled to the dressing interface 107 by conduit 121 and conduit 122 as described above. In some embodiments, the negative pressure conduit 130 and the pressure sensing conduit 122 may be combined in a single fluid conductor that can be, for example, a multi lumen tubing comprising a central primary lumen that functions as the negative pressure conduit 130 for delivering negative pressure to the dressing interface 107 and several peripheral auxiliary lumens that function as the pressure sensing conduit 122 for sensing the pressure that the dressing interface 107 delivers to the tissue interface 108. In this type of therapy unit wherein the pressure sensor 120 is removed from and indirectly coupled to the dressing interface 107, the negative pressure measured by the pressure sensor 120 may be different from the wound pressure (WP) actually being applied to the tissue site 150. Such pressure differences must be approximated in order to adjust the negative-pressure source 104 to deliver the pump pressure (PP) necessary to provide the desired or target pressure (TP) to the tissue interface 108. Moreover, such pressure differences and predictability may be exacerbated by viscous fluids such as exudates being produced by the tissue site or utilizing a single therapy device including a pressure sensor to deliver negative pressure to multiple tissue sites on a single patient.

[0095] What is needed is a pressure sensor that is integrated within the dressing interface 107 so that the pressure sensor is proximate the tissue interface 108 when disposed on the tissue site in order to provide a more accurate reading of the wound pressure (WP) being provided within the therapy environment of the dressing 102. The integrated pressure sensor may be used with or without the remote pressure sensor 120 that is indirectly coupled to the dressing interface 107. In some example embodiments, the dressing interface 107 may comprise a housing having a therapy cavity that opens to the tissue site when positioned thereon. The integrated pressure sensor may have a sensing portion disposed within the therapy cavity along with other sensors including, for example, a temperature sensor, a humidity sensor, and a pH sensor. The sensors may be electrically coupled to the controller 110 outside the therapy cavity to provide data indicative of the pressure, temperature, humidity, and acidity properties within the therapeutic space of the therapy cavity. The sensors may be electrically coupled to the controller 110, for example, by wireless means. Systems, apparatuses, and methods described herein provide the advantage of more accurate measurements of these properties, as well as other significant advantages described below in more detail.

[0096] As indicated above, the dressing 102 may include the cover 106, the dressing interface 107, and the tissue interface 108. Referring now to Figures 4, 5A, 5B, 5C, 6A, 6B, and 7, a first dressing is shown comprising a dressing interface 400, a cover or drape 406, and a tissue interface or manifold 408 disposed adjacent a tissue site 410, all of which may be functionally similar in part to the dressing interface 107, the cover 106, and the tissue interface 108, respectively, as described above. In one example embodiment, the dressing interface 400 may comprise a housing 401 and a wall 402 disposed within the housing 401 wherein the wall 402 forms a recessed space or a therapy cavity 403 that opens to the manifold 408 when disposed at the tissue site 410 and a component cavity 404 opening away from the tissue site 410 of the upper portion of the dressing interface 400. In some embodiments, sensing portions of various sensors may be disposed within the therapy cavity 403, and electrical devices associated with the sensors may be disposed within the component cavity 404 and electrically coupled to the sensing portions through the wall 402. Electrical devices disposed within the component cavity 404 may include components associated with some example embodiments of the therapy system of Figure 1. Although the dressing interface 400 and the therapy cavity 403 are functionally similar to the dressing interface 107 as described above, the dressing interface 400 further comprises the wall 402, the sensors, and the associated electrical devices described below in more detail. In some embodiments, the housing 401 may further comprise a neck portion or neck 407 fluidly coupled to a conduit 405. In some embodiments, the housing 401 may further comprise a flange portion or flange 409 having flow channels (see Figure 8) configured to be fluidly coupled to the therapy cavity 403 when disposed on the manifold 408.

[0097] In an advantageous embodiment, the housing 401 may include a communication port 412 that may be used to couple one of more external devices to the sensor assembly 425 of the dressing interface 400. By way of example and not limitation, communications port 412 may comprise a USB 3.0 port that couples to a USB 3.0 connector 412A on the circuit board 432 that supports the wireless communications module 422 and that couples the sensor assembly 425 of the dressing interface 400 to one or more of a display and/or operator interface, one of more supplemental sensors, a Bluetooth module, or an external power supply. One example of a display or operator interface may be a mobile phone or a computer tablet that an operator uses to control and communicate with the sensor assembly 425 of the dressing interface 400.

[0098] In an advantageous embodiment, the housing 401 may include a product identifier 499 that may be read by a therapy control device in order to accurately identify the dressing interface 400. As will be explained below in greater detail, the therapy control device or therapy controller is capable of identifying the exact product and model of dressing interface 400 and can then select the correct therapy protocol(s) and operating parameters for dressing interface 400. By way of example and not limitation, product identifier 499 may be a bar code, a Q code, an RFID tag (passive or active), a near- field communications (NFC) tag, or the like. The therapy controller is simply brought within close proximity of the product identifier 499 in order to automatically read the product and model information and thereby select, for example, the proper graphical user interface (GUI) to allow an operator to follow the correct therapy protocol(s) and operating parameters for dressing interface 400. By way of example, a camera in the therapy controller may be used to read a product identifier 499 that is a bar code or Q code in order to identify the product and model information of dressing interface 499. Alternatively, an NFC-enabled transceiver in the therapy controller may be used to read a product identifier 499 that is an NFC tag in order to identify the product and model information of dressing interface 400. Alternatively, an RFID-enabled transceiver in the therapy controller may be used to read a product identifier 499 that is an RFID tag.

[0099] In some example embodiments, the neck 407 of the housing 401 may include portions of both the therapy cavity 403 and the component cavity 404. That portion of the neck 407 extending into the therapy cavity 403 is fluidly coupled to the conduit 405, while the portion extending into the component cavity 404 may contain some of the electrical devices. In some example embodiments, the conduit 405 may comprise a primary lumen 430 and auxiliary lumens 435 fluidly coupled by the neck 407 of the housing 401 to the therapy cavity 403. The primary lumen 430 is similar to the negative pressure conduit 130 that may be coupled indirectly to the negative-pressure source 104. The auxiliary lumens 435 are collectively similar to the vent conduit 135 that may be fluidly coupled to the regulator 118 for purging fluids from the therapy cavity 403. [00100] In some embodiments, the component cavity 404 containing the electrical devices may be open to the ambient environment such that the electrical devices are exposed to the ambient environment. In other example embodiments, the component cavity 404 may be closed by a cover such as, for example, a cap 411 to protect the electrical devices. In still other embodiments, the component cavity 404 covered by the cap 411 may still be vented to the ambient environment to provide cooling to the electrical devices and a source of ambient pressure for a pressure sensor disposed in the therapy cavity 403 as described in more detail below. The first dressing may further comprise a drape ring 413 covering the circumference of the flange 409 and the adjacent portion of the drape 406 to seal the therapy cavity 403 of the housing 401 over the manifold 408 and the tissue site 410. In some embodiments, the drape ring 413 may comprise a polyurethane film including and an attachment device such as, for example, an acrylic, polyurethane gel, silicone, or hybrid combination of the foregoing adhesives (not shown) to attach the drape ring 413 to the flange 409 and the drape 406. The attachment device of drape ring 413 may be a single element of silicon or hydrocolloid with the adhesive on each side that functions as a gasket between the drape 406 and the flange 409. In some embodiments, the drape ring 413 may be similar to the cover 106 and/or the attachment device described above in more detail.

[00101] In some embodiments, a pressure sensor 416, a temperature and humidity sensor 418, and a pH sensor 420 (collectively referred to below as “the sensors”) may be disposed in the housing 401 with each one having a sensing portion extending into the therapy cavity 403 of the housing 401 and associated electronics disposed within the component cavity 404. The housing 401 may include other types of sensors, or combinations of the foregoing sensors, such as, for example, oxygen sensors. In some example embodiments, the sensors may be coupled to or mounted on the wall 402 and electrically coupled to electrical components and circuits disposed within the component cavity 404 by electrical conductors extending through the wall 402. In some preferred embodiments, the electrical conductors extend through pathways in the wall 402 while keeping the therapy cavity 403 electrically and pneumatically isolated from the component cavity 404. For example, the wall 402 may comprise a circuit board 432 on which the electrical circuits and/or components may be printed or mounted. In some other examples, the circuit board 432 may be the wall 402 that covers an opening between the therapy cavity 403 and the component cavity 404, and pneumatically seals the therapy cavity 403 from the component cavity 404 when seated over the opening.

[00102] In some embodiments, the electrical circuits and/or components associated with the sensors that are mounted on the circuit board 432 within the component cavity 404 may be electrically coupled to the controller 110 to interface with the rest of the therapy system 100 as described above. In some embodiments, for example, the electrical circuits and/or components may be electrically coupled to the controller 110 by a conductor that may be a component of the conduit 405. In some other preferred embodiments, a communications module 422 may be disposed in the component cavity 404 of the housing 401 and mounted on the circuit board 432 within the component cavity 404. Using a wireless communications module 422 has the advantage of eliminating an electrical conductor between the dressing interface 400 and the integrated portion of the therapy system 100 that may become entangled with the conduit 405 when in use during therapy treatments. For example, the electrical circuits and/or components associated with the sensors along with the terminal portion of the sensors may be electrically coupled to the controller 110 by wireless means such as an integrated device implementing Bluetooth^® Low Energy wireless technology. More specifically, the communications module 422 may be a Bluetooth^® Low Energy system-on-chip that includes a microprocessor (an example of the microprocessors referred to hereinafter) such as the nRF51822 chip available from Nordic Semiconductor. The wireless communications module 422 may be implemented with other wireless technologies suitable for use in the medical environment.

[00103] In some embodiments, a voltage regulator 423 for signal conditioning and a power source 424 may be disposed within the component cavity 404 of the housing 401, mounted on the circuit board 432. The power source 424 may be secured to the circuit board 432 by a bracket 426. The power source 424 may be, for example, a battery that may be a coin battery having a low-profile that provides a 3 -volt source for the communications module 422 and the other electronic components within the component cavity 404 associated with the sensors. In some example embodiments, the sensors, the electrical circuits and/or components associated with the sensors, the wall 402 and/or the circuit board 432, the communications module 422, and the power source 424 may be integrated into a single package and referred to hereinafter as a sensor assembly 425 as shown in Figure 6B. In some preferred embodiments, the wall 402 of the sensor assembly 425 may be the circuit board 432 itself as described above that provides a seal between tissue site 410 and the atmosphere when positioned over the opening between the therapy cavity 403 and the component cavity 404 of the housing 401 and functions as the wall 402 within the housing 401 that forms the therapy cavity 403.

[00104] Referring now to Figures 8A and 8B, a perspective view and a bottom view, respectively, of a bottom surface of the flange 409 facing the manifold 408 is shown. In some embodiments, the bottom surface may comprise features or channels to direct the flow of liquids and/or exudates away from the sensors out of the therapy cavity 403 into the primary lumen 430 when negative pressure is being applied to the therapy cavity 403. In some embodiments, these channels may be molded into the bottom surface of the flange 409 to form a plurality of serrated guide channels 437, perimeter collection channels 438, and intermediate collection channels 439. The serrated guide channels 437 may be positioned and oriented in groups on bottom surface to directly capture and channel at least half of the liquids being drawn into the therapy cavity 403 with the groups of serrated guide channels 437, and indirectly channel a major portion of the balance of the liquids being drawn into the therapy cavity 403 between the groups of serrated guide channels 437. In addition, perimeter collection channels 438 and intermediate collection channels 439 redirect the flow of liquids that are being drawn in between the groups of radially-oriented serrated guide channels 437 into the guide channels 437. An example of this redirected flow is illustrated by bolded flow arrows 436. In some example embodiments, a portion of the housing 401 within the therapy cavity 403 may comprise a second set of serrated guide channels 427 spaced apart and radially-oriented to funnel liquids being drawn into the therapy cavity 403 from the flange 409 into the primary lumen 430. In other example embodiments of the bottom surface of the flange 409 and that portion of the housing 401 within the therapy cavity 403, the channels may be arranged in different patterns.

[00105] As indicated above, the sensor assembly 425 may comprise a pressure sensor 416, a humidity sensor 418, a temperature sensor as a component of either the pressure sensor 416 or the humidity sensor 418, and a pH sensor 420. Each of the sensors may comprise a sensing portion extending into the therapy cavity 403 of the housing 401 and a terminal portion electrically coupled to the electrical circuits and/or components within the component cavity 404. Referring more specifically to Figures 4, 6A, 6B, and 7A-7D, the housing 401 may comprise a sensor bracket 441 that may be a molded portion of the housing 401 within the therapy cavity 403 in some embodiments. The sensor bracket 441 may be structured to house and secure the pressure sensor 416 on the circuit board 432 within the therapy cavity 403 of the sensor assembly 425 that provides a seal between tissue site 410 and the atmosphere as described above. In some embodiments, the pressure sensor 416 may be a differential gauge comprising a sensing portion 442 and a terminal portion or vent 443. The vent 443 of the pressure sensor 416 may be fluidly coupled through the circuit board 432 to the component cavity 404 and the atmosphere by a vent hole 444 extending through the circuit board 432. Because the component cavity 404 is vented to the ambient environment, the vent 443 of the pressure sensor 416 is able to measure the wound pressure (WP) with reference to the ambient pressure. The sensing portion 442 of the pressure sensor 416 may be positioned in close proximity to the manifold 408 to optimize fluid coupling and accurately measure the wound pressure (WP) at the tissue site 410. In some embodiments, the pressure sensor 416 may be a piezo-resistive pressure sensor having a pressure sensing element covered by a dielectric gel such as, for example, a Model 1620 pressure sensor available from TE Connectivity. The dielectric gel provides electrical and fluid isolation from the blood and wound exudates in order to protect the sensing element from corrosion or other degradation. This allows the pressure sensor 416 to measure the wound pressure (WP) directly within the therapy cavity 403 of the housing 401 proximate to the manifold 408 as opposed to measuring the wound pressure (WP) from a remote location. In some embodiments, the pressure sensor 416 may be a gauge that measures the absolute pressure that does not need to be vented.

[00106] In some embodiments, the pressure sensor 416 also may comprise a temperature sensor for measuring the temperature at the tissue site 410. In other embodiments, the humidity sensor 418 may comprise a temperature sensor for measuring the temperature at the tissue site 410. The sensor bracket 441 also may be structured to support the humidity sensor 418 on the circuit board 432 of the sensor assembly 425. In some embodiments, the humidity sensor 418 may comprise a sensing portion that is electrically coupled through the circuit board 432 to a microprocessor mounted on the other side of the circuit board 432 within the component cavity 404. The sensing portion of the humidity sensor 418 may be fluidly coupled to the space within the therapy cavity 403 that includes a fluid pathway 445 extending from the therapy cavity 403 into the primary lumen 430 of the conduit 405 as indicated by the bold arrow to sense both the humidity and the temperature. The sensing portion of the humidity sensor 418 may be positioned within the fluid pathway 445 to limit direct contact with bodily fluids being drawn into the primary lumen 430 from the tissue site 410. In some embodiments, the space within the therapy cavity 403 adjacent the sensing portion of the humidity sensor 418 may be purged by venting that space through the auxiliary lumens 435 as described in more detail below. As indicated above, the humidity sensor 418 may further comprise a temperature sensor (not shown) as the location within the fluid pathway 445 is well-suited to achieve accurate readings of the temperature of the fluids. In some embodiments, the humidity sensor 418 that comprises a temperature sensor may be a single integrated device such as, for example, Model HTU28 humidity sensor also available from TE Connectivity.

[00107] Referring now to Figures 9A and 9B, the pH sensor 420 may comprise a sensing portion disposed within the therapy cavity 403 that is electrically coupled through the circuit board 432 to a front-end amplifier 421 mounted on the other side of the circuit board 432 within the component cavity 404. The front-end amplifier 421 comprises analog signal conditioning circuitry that includes sensitive analog amplifiers such as, for example, operational amplifiers, filters, and application-specific integrated circuits. The front-end amplifier 421 measures minute voltage potential changes provided by the sensing portions to provide an output signal indicative of the pH of the fluids. The sensing portion of the pH sensor 420 may be fluidly coupled to the space within the therapy cavity 403 by being positioned in the fluid pathway 445 that extends into the primary lumen 430 as described above to sense the pH changes. The sensing portion of the pH sensor 420 may be formed and positioned within the fluid pathway 445 so that the sensing portion directly contacts the wound fluid without contacting the wound itself so that the sensing portion of the pH sensor 420 does not interfere with the wound healing process. In some embodiments, the space within the therapy cavity 403 adjacent the sensing portion of the pH sensor 420 also may be purged by venting that space through the auxiliary lumens 435 as described in more detail below. In some embodiments, the pH sensor 420 may be, for example, pH sensor 450 shown in Figure 9A that comprises a pair of printed medical electrodes including a working electrode 451 and a reference electrode 452. In some embodiments, the working electrode 451 may have a node being substantially circular in shape at one end and having a terminal portion at the other end, and the reference electrode 452 may have a node being substantially semicircular in shape and disposed around the node of the working electrode 451.

[00108] In some example embodiments, the working electrode 451 may comprise a material selected from a group including graphene oxide ink, conductive carbon, carbon nanotube inks, silver, nano-silver, silver chloride ink, gold, nano-gold, gold-based ink, metal oxides, conductive polymers, or a combination thereof. This working electrode 451 further comprise a coating or film applied over the material wherein such coating or film may be selected from a group including metal oxides such as, for example, tungsten, platinum, iridium, ruthenium, and antimony oxides, or a group of conductive polymers such as polyaniline and others so that the conductivity of the working electrode 451 changes based on changes in hydrogen ion concentration of the fluids being measured or sampled. In some example embodiments, the reference electrode 452 may comprise a material selected from a group including silver, nano-silver, silver chloride ink, or a combination thereof. The pH sensor 450 may further comprise a coating 453 covering the electrodes that insulates and isolates the working electrode 451 from the reference electrode 452 and the wound fluid, except for an electrical coupling space 454 between the nodes of the working electrode 451 and the reference electrode 452. The coating 453 does not cover the terminal portions of the working electrode 451 and the reference electrode 452 to form terminals 455 and 456, respectively, adapted to be electrically coupled to the front-end amplifier 421.

[00109] In some example embodiments, the terminal portion of the working electrode 451 and the reference electrode 452 may extend through the circuit board 432 and electrically coupled to the front-end amplifier 421 of the pH sensor 450. As indicated above, the front-end amplifier 421 of the pH sensor 450 measures minute potential changes between the working electrode 451 and the reference electrode 452 that result from a change in hydrogen ion concentration of the wound fluid as the pH of the wound fluid changes. The front-end amplifier 421 may be, for example, an extremely accurate voltmeter that measures the voltage potential between the working electrode 451 and the reference electrode 452. The front-end amplifier 421 may be for example a high impedance analog front-end (AFE) device such as the LMP7721 and LMP91200 chips that are available from manufacturers such as Texas Instruments or the AD7793 and AD8603 chips that are available from manufacturers such as Analog Devices.

[00110] In some other embodiments, the pH sensor 420 may include a third electrode such as, for example, pH sensor 460 shown in Figure 9B that comprises a third electrode or a counter electrode 462 in addition to the working electrode 451 and the reference electrode 452 of the pH sensor 450. The counter electrode 462 also comprises a node partially surrounding the node of the working electrode 451 and a terminal 466 adapted to be electrically coupled to the front-end amplifier 421. Otherwise, the pH sensor 460 is substantially similar to the pH sensor 450 described above as indicated by the reference numerals. The counter electrode 462 is also separated from the working electrode 451 and is also insulated from the wound fluid and the other electrodes by the coating 453 except in the electrical conductive space 454. The counter electrode 462 may be used in connection with the working electrode 451 and the reference electrode 452 for the purpose of error correction of the voltages being measured. For example, the counter electrode 462 may possess the same voltage potential as the potential of the working electrode 451 except with an opposite sign so that any electrochemical process affecting the working electrode 451 will be accompanied by an opposite electrochemical process on the counter electrode 462. Although voltage measurements are still being taken between the working electrode 451 and the reference electrode 452 by the analog front-end device of the pH sensor 460, the counter electrode 462 may be used for such error correction and may also be used for current readings associated with the voltage measurements. Custom printed electrodes assembled in conjunction with a front-end amplifier may be used to partially comprise pH sensors such as the pH sensor 450 and the pH sensor 460 may be available from several companies such as, for example, GSI Technologies, Inc. and Dropsens.

[00111] As described above, the sensing portions of the sensors may all be disposed within the therapy cavity 403 and electrically coupled through the circuit board 432 to the front-end amplifier 421 and the communications module 422 mounted on the other side of the circuit board 432 within the component cavity 404. In some embodiments, sensor assembly 425 may comprise a processing element that may include the communications module 422 which may include the microprocessor and/or the wireless communications chip described above. The processing element may further include the front- end amplifier 421 and any other components that are disposed within the component cavity 404. The processing element may be electrically coupled to the sensing portions of the sensors for receiving property signals from the sensing portions that are indicative of the pressure, humidity, temperature, and the pH of the fluid at the tissue site in order to determine the flow characteristics of the system and the progression of wound healing as described in more detail below.

[00112] The systems, apparatuses, and methods described herein may provide other significant advantages. For example, some therapy systems are a closed system wherein the pneumatic pathway is not vented to ambient air, but rather controlled by varying the supply pressure or the pump pressure (PP) to achieve the desired target pressure (TP) in a continuous pressure mode, an intermittent pressure mode, or a variable target pressure mode as described above in more detail with reference to Figures 2A and 2B. In some embodiments of the closed system, the wound pressure (WP) being measured in the dressing interface 107 may not drop in response to a decrease in the supply pressure or the pump pressure (PP) as a result of a blockage within the dressing interface 107 or other portions of the pneumatic pathway. In some embodiments of the closed system, the supply pressure or the pump pressure (PP) may not provide airflow to the tissue interface 108 frequently enough that may result in the creation of a significant head pressure or blockages within the dressing interface 107 that also would interfere with sensor measurements being taken by the dressing interface 400 as described above. The head pressure in some embodiments may be defined as a difference in pressure (DP) between a negative pressure set by a user or caregiver for treatment, i.e., the target pressure (TP), and the negative pressure provided by a negative pressure source that is necessary to offset the pressure drop inherent in the fluid conductors, i.e., the supply pressure or the pump pressure (PP), in order to achieve or reach the target pressure (TP). For example, the head pressure that a negative pressure source needs to overcome may be as much as 75 mmHg. Problems may occur in such closed systems when a blockage occurs in the pneumatic pathway of the fluid conductors that causes the negative pressure source to increase to a value above the normal supply pressure or the pump pressure (PP) as a result of the blockage. For example, if the blockage suddenly clears, the instantaneous change in the pressure being supplied may cause harm to the tissue site. [00113] Some therapy systems have attempted to compensate for head pressure by introducing a supply of ambient air flow into the therapeutic environment, e.g., the therapy cavity 403, by providing a vent with a fdter on the housing 401 of the dressing interface 400 to provide ambient air flow into the therapeutic environment as a controlled leak. However, in some embodiments, the fdter may be blocked when the interface dressing is applied to the tissue site or when asked at least blocked during use. Locating the fdter in such a location may also be problematic because it is more likely to be contaminated or compromised by other chemicals and agents associated with treatment utilizing instillation fluids that could adversely affect the performance of the fdter and the vent itself.

[00114] The embodiments of the therapy systems described herein overcome the problems associated with having a large head pressure in a closed pneumatic environment, and the problems associated with using a vent disposed on or adjacent the dressing interface. More specifically, the embodiments of the therapy systems described above comprise a pressure sensor, such as the pressure sensor 416, disposed within the pneumatic environment, i.e., in situ, that independently measures the wound pressure (WP) within the therapy cavity 403 of the housing 401 as described above rather than doing so remotely. Consequently, the pressure sensor 416 is able to instantaneously identify dangerously high head pressures and/or blockages within the therapy cavity 403 adjacent the manifold 408. Because the auxiliary lumens 435 are not being used for pressure sensing, the auxiliary lumens 435 may be fluidly coupled to a fluid regulator such as, for example, the regulator 118 in Figure 1, that may remotely vent the therapeutic environment within the therapy cavity 403 to the ambient environment or fluidly couple the therapeutic environment to a source of positive pressure. The regulator 118 may then be used to provide ambient air or positive pressure to the therapeutic environment in a controlled fashion to “purge” the therapeutic environment within both the therapy cavity 403 and the primary lumen 430 to resolve the problems identified above regarding head pressures and blockages, and to facilitate the continuation of temperature, humidity, and pH measurements as described above.

[00115] Using a regulator to purge the therapeutic environment is especially important in therapy systems such as those disclosed in Figures 1 and 3 that include both negative pressure therapy and instillation therapy for delivering therapeutic liquids to a tissue site. For example, in one embodiment, fluid may be instilled to the tissue site 150 by applying a negative pressure from the negative-pressure source 104 to reduce the pressure at the tissue site 150 to draw the instillation liquid into the dressing 102 as indicated at 302. In another embodiment, liquid may be instilled to the tissue site 150 by applying a positive pressure from the negative-pressure source 104 (not shown) or the instillation pump 116 to force the instillation liquid from the solution source 114 to the tissue interface 108 as indicated at 304. Such embodiments may not be sufficient to remove all the instillation liquids from the therapeutic environment, or may not be sufficient to remove the instillation liquids quickly enough from the therapeutic environment to facilitate the continuation of accurate temperature, humidity, and pH measurements. Thus, the regulator 118 may be used to provide ambient air or positive pressure to the therapeutic environment to more completely or quickly purge the therapeutic environment to obtain the desired measurements as described above.

[00116] In embodiments of therapy systems that include an air flow regulator comprising a valve such as the solenoid valve described above, the valve provides controlled airflow venting or positive pressure to the therapy cavity 403 as opposed to a constant airflow provided by a closed system or an open system including a fdter in response to the wound pressure (WP) being sensed by the pressure sensor 416. The controller 110 may be programmed to periodically open the solenoid valve as described above allowing ambient air to flow into the therapy cavity 403, or applying a positive pressure into the therapy cavity 403, at a predetermined flow rate and/or for a predetermined duration of time to purge the pneumatic system including the therapy cavity 403 and the primary lumen 430 of bodily liquids and exudates so that the humidity sensor 418 and the pH sensor 420 provide more accurate readings and in a timely fashion. This feature allows the controller to activate the solenoid valve in a predetermined fashion to purge blockages and excess liquids that may develop in the fluid pathways or the therapy cavity 403 during operation. In some embodiments, the controller may be programmed to open the solenoid valve for a fixed period of time at predetermined intervals such as, for example, for five seconds every four minutes to mitigate the formation of any blockages.

[00117] In some other embodiments, the controller may be programmed to open the solenoid valve in response to a stimulus within the pneumatic system rather than, or in addition to, being programmed to function on a predetermined therapy schedule. For example, if the pressure sensor is not detecting pressure decay in the canister, this may be indicative of a column of fluid forming in the fluid pathway or the presence of a blockage in the fluid pathway. Likewise, the controller may be programmed to recognize that an expected drop in canister pressure as a result of the valve opening may be an indication that the fluid pathway is open. The controller may be programmed to conduct such tests automatically and routinely during therapy so that the patient or caregiver can be forewarned of an impending blockage. The controller may also be programmed to detect a relation between the extent of the deviation in canister pressure resulting from the opening of the valve and the volume of fluid with in the fluid pathway. For example, if the pressure change within the canister is significant when measured, this could be an indication that there is a significant volume of fluid within the fluid pathway. However, if the pressure change within the canister is not significant, this could be an indication that the plenum volume was larger.

[00118] The systems, apparatuses, and methods described herein may provide other significant advantages over dressing interfaces currently available. For example, a patient may require two dressing interfaces for two tissue sites, but wish to use only a single therapy device to provide negative pressure to and collect fluids from the multiple dressing interfaces to minimize the cost of therapy. In some therapy systems currently available, the two dressing interfaces would be fluidly coupled to the single therapy device by a Y -connector. The problem with this arrangement is that the Y -connector embodiment would not permit the pressure sensor in the therapy device to measure the wound pressure in both dressing interfaces independently from one another. A significant advantage of using a dressing interface including in situ sensors, e.g., the dressing interface 400 including the sensor assembly 425 and the pressure sensor 416, is that multiple dressings may be fluidly coupled to the therapy unit of a therapy system and independently provide pressure data to the therapy unit regarding the associated dressing interface. Each dressing interface 400 including in situ sensors that is fluidly coupled to the therapy unit for providing negative pressure to the tissue interface 108 and collecting fluids from the tissue interface 108 has the additional advantage of being able to collect and monitor other information at the tissue site including, for example, humidity data, temperature data, and the pH data being provided by the sensor assembly 425 in addition to the pressure data and other data that might be available from other sensors in the sensor assembly 425.

[00119] Another advantage of using the dressing interface 400 that includes a pressure sensor in situ such as, for example, the pressure sensor 416, is that the pressure sensor 416 can more accurately monitor the wound pressure (WP) at the tissue site and identify blockages and fluid leaks that may occur within the therapeutic space or other distribution components of the system as described in more detail above. Another advantage of using the dressing interface 400 that includes a pressure sensor in situ is that one of the auxiliary lumens 435 are freed up to vent or actively purge the sensing portions of the sensors within the therapeutic cavity 403 so that meaningful data regarding the sensing properties can be obtained on a timely basis for providing the therapy and detecting the flow characteristics of the system and the status of wound healing. Yet another advantage of using a dressing interface including in situ sensors, e.g., the dressing interface 400, is that the sensor assembly 425 provides additional data including pressure, temperature, humidity, and pH of the fluids being drawn from the tissue site that facilitates improved control algorithms for detecting flow characteristics within the system and profiling the status of wound healing. Such improvements further assist the caregiver with additional information provided by the therapy unit of the therapy system to optimize the wound therapy being provided and the overall healing progression of the tissue site when combined with appropriate control logic.

[00120] As indicated above, the processing element of the sensor assembly 425 may receive property signals indicative of the pressure, the humidity, the temperature, and the pH within the therapy cavity 403 that may be transmitted to the controller 110 of the system for applying therapy to the tissue site and detecting the flow characteristics of the system and the status of wound healing at the tissue site. In some embodiments, the flow characteristics may include the detection of blockages, fluidly leaks, air leaks, and desiccation conditions associated with the dressing interface and the system. The property signals associated with the fluids at a specific time may be processed and logged by the controller 110 and assessed with previous property signal measurements. The controller 110 may also be programmed with a negative pressure control algorithm that assesses the logged property signals to assess the status of wound healing and with that assessment adjust the pump pressure (PP) and/or the pump duty cycle (PD) if necessary to maintain the wound pressure (WP) proximate the desired target pressure (TP). [00121] Referring to Figure 10, a flowchart is shown that illustrates a method for treating a tissue site in some embodiments of therapy systems including, for example, the therapy system 100. More specifically, such method may utilize a dressing interface or sensing pad such as, for example, the dressing interface 400 of Figure 4, for applying negative-pressure therapy with fluid instillation therapy and sensing properties of wound exudates extracted from a tissue site as shown at 600. A tissue interface such as the tissue interface 108 may be placed within, over, on, or otherwise proximate a tissue site at 601. A cover such as the cover 106 may be placed over the tissue interface 108 and sealed to an attachment surface near the tissue site 150. For example, the cover 106 may be sealed to undamaged epidermis peripheral to a tissue site. Thus, the dressing 102 provides a sealed therapeutic environment proximate to a tissue site, substantially isolated from the external environment, while the negative- pressure source 104 reduces the pressure within the sealed therapeutic environment and the instillation pump 116 provides fluids to the sealed therapeutic environment as described above. In some embodiments, the method may further comprise applying the sensing pad or dressing interface to the tissue interface at 602. More specifically, applying the sensing pad may include positioning the housing on the dressing interface so that the aperture of the housing is in fluid communication with the tissue interface. The dressing interface may comprise a wall disposed within the housing to form a therapy cavity within the housing and a component cavity fluidly sealed from the therapy cavity, wherein the therapy cavity opens to the aperture as described above. Such dressing interface may further comprise a negative-pressure port fluidly coupled to the therapy cavity and adapted to be fluidly coupled to a negative-pressure source as described above. The dressing interface may further comprise a processing element disposed in the component cavity or outside the therapy cavity, similar to the processing element described above.

[00122] Still referring to 602, the method may further comprise connecting the sensing pad to a wound therapy device such as, for example, the therapy system 100. Connecting the sensing pad may include coupling the therapy cavity of the sensing pad to a negative-pressure source and to a vent as described above, and electrically coupling the processing element to a controller of the therapy system such as, for example, the controller 110. The sensing pad or the dressing interface may further comprise a pH sensor, a temperature sensor, a humidity sensor, and a pressure sensor, each having a sensing portion disposed within the therapy cavity and each electrically coupled to the processing element through the wall as described above.

[00123] Referring now to 603, the method may further comprise initializing therapy settings for both the negative pressure therapy and the fluid instillation therapy to be provided for treatment. The therapy settings may include, for example, the initial settings for the sensor readings of the pH sensor, the temperature sensor, the humidity sensor, and the pressure sensor that may be stored on the controller 110. The therapy settings for the negative pressure therapy phase may also include, for example, any initial values associated with the pump pressure (PP), the pump duty cycle (PD), or the desired target pressure (TP) of the negative-pressure source 104. The therapy settings for the fluid instillation therapy phase may further include any initial values associated with the fill volume and the soak time, as well as an instillation pump pressure (IP), an instillation duty cycle (ID), and a desired fluid pressure (FP) of the instillation pump 116 for the fluid instillation therapy phase of the therapy treatment.

[00124] After the therapy settings are initialized, the method may further comprise a caregiver or patient turning on the therapy system 100 to begin applying a desired therapy treatment at 604. The desired therapy treatment may include negative pressure therapy, instillation therapy, or other therapy for treating the tissue site as indicated. In some embodiments, for example, the method may comprise applying negative-pressure therapy at 605 to the therapy cavity of the dressing interface to draw fluids from the tissue interface into the therapy cavity and exiting out of the reduced-pressure port. The method may further comprise sensing the pH, temperature, humidity, and pressure properties of the fluids flowing through therapy cavity utilizing the sensing portion of the sensors which may provide property signals indicative of such properties to the processing element. Applying negative-pressure therapy may further comprise providing the property signals from the processing element to the controller of the therapy system for processing the property signals and treating the tissue site in response to the property data being collected and processed by the therapy system.

[00125] In some embodiments, the method may further comprise applying fluid instillation therapy at 606 to the therapy cavity of the dressing interface to provide fluids to the therapy cavity either directly to the therapy cavity of the dressing interface or indirectly from another location on the dressing as described above, and ultimately exiting out of the reduced-pressure port. In some embodiments, fluid instillation therapy may be provided prior to or concurrent with negative pressure therapy as described in more detail above. The method may further comprise sensing the pH, temperature, humidity, and pressure properties of the fluids flowing through therapy cavity utilizing the sensing portion of the sensors which may provide property signals indicative of such properties to the processing element. Applying fluid instillation therapy may further comprise providing the property signals from the processing element to the controller of the therapy system for processing the property signals and treating the tissue site in response to the sensor data being collected and processed by the therapy system.

[00126] Referring to decision block 607, the method may further comprise turning off the therapy treatment when receiving a signal from a caregiver, a patient, or from a control algorithm stored on the controller of the therapy system for assessing the sensor data and corresponding health of the tissue site as described in more detail below. If the therapy system is turned off (YES) ending the therapy treatment at 608, the method may further comprise removing the dressing interface, the cover, and the sensing pad at 609 after the therapy system is turned off as indicated. If no such signal is received to turn off the therapy treatment, the method in some embodiments may loop back to 605 to continue applying the negative-pressure therapy with fluid instillation to the dressing interface and the tissue site. When the method loops back to 605, the method may include commands provided by the control algorithms to continue controlling the negative pressure therapy by increasing the pump pressure (PP) or the pump duty cycle (PD) along with the fluid instillation therapy by adjusting the instillation pump pressure (IP) or the instillation duty cycle (ID).

[00127] Figure 11 is a schematic block diagram illustrating an embodiment of a control algorithm that may comprise a negative pressure control algorithm that may be utilized when applying the negative-pressure therapy within the tissue treatment method 600, hereinafter referred to as the negative pressure control algorithm 605. The negative pressure control algorithm 605 may include the detection of dressing flow characteristics within the system and an assessment of sensor properties based on the property data stored on the controller of the therapy system. Figures 13A-13C show flow charts illustrating various methods of some embodiments that may be configured to operate within the negative pressure control algorithm 605 of Figure 11. The negative pressure therapy algorithm 605 may commence by initializing the therapy settings at 603 including the sensor settings by setting initial values of the property signals provided by the sensors to the processing element of the dressing interface and ultimately to the controller of the therapy system as indicated for processing and assessment.

[00128] The negative pressure control algorithm 605 may include a wound pressure control 610 as shown in Figure 11 that compares wound pressure (WP) to the target pressure (TP), and then provides commands to increase or decrease the pump duty cycle (PD) accordingly and/or log the sensor readings of the sensor properties at 650. Referring more specifically to Figure 13A, if the wound pressure (WP) is greater than the target pressure (TP) at 611 (YES), the wound pressure control 610 may generate a command to vent the therapy cavity at 612 as described above and a command to reduce the pump duty cycle (PD) at 613. After the pump duty cycle (PD) is reduced, the property signals may then be logged in the controller of the therapy system as indicated at 650 for further processing by a set of assessment algorithms as indicated at 651. If the wound pressure (WP) is not greater than the target pressure (TP) at 611 (NO), the wound pressure (WP) is again compared to the target pressure (TP) at 614. If the wound pressure (WP) is not less than the target pressure (TP), i.e., greater than or equal to the target pressure (TP), the wound pressure control 610 may generate a command to maintain or reduce the pump duty cycle (PD) at 615 and the property signals may then be logged in the controller of the therapy system as indicated at 650 for further processing by the assessment algorithms 651. However, if the wound pressure (WP) is less than or equal to the target pressure (TP), the wound pressure control 610 may generate a command to increase the pump duty cycle (PD) at 616. When the pump duty cycle (PD) is increased, the negative pressure control algorithm 605 in some embodiments may proceed to dressing-alert algorithms including, for example, a blockage detection algorithm and fluid leak detection algorithm shown generally at 620 in Figure 11 (shown more specifically in Figure 13B), and an air leak detection algorithm and desiccation detection algorithm shown generally at 640 in Figure 11 (shown more specifically in Figure 13C).

[00129] In some embodiments of a therapy system such as, for example, therapy system 100, the therapy system may comprise a user interface coupled to the controller 110. Referring more specifically to Figure 12, a block diagram of one example embodiment of a user interface, user interface 660, that may comprise a variety of alerts and alarms associated with the dressing flow characteristics of Figure 11. These alerts and/or alarms associated with the dressing flow characteristics may comprise, for example, alerts and/or alarms for a blockage condition 661, a fluid leak condition 662, an air leak condition 663, or a desiccation condition 664. The negative pressure control algorithm may be programmed to generate an alarm based on the occurrence of a predetermined number of alerts such as, for example, generating alarm after the occurrence of three alerts. The user interface 660 may also provide alerts and/or alarms that may be associated with wound progress 665 and/or canister-full alert 667 based on the fluid properties being provided by the sensing pad or the dressing interface 400, for example. All of the fluid properties and associated alerts and/or alarms identified above may be selectively provided for each wound dressing (WD#1, WD#2 or WD#3) such as, for example, wound dressings substantially similar to the dressing 102, that may be fluidly and electrically coupled to the therapy system 100. For example, a patient or caregiver may select a desired wound dressing by setting a wound dressing selection switch 668. Alternatively, the controller of the therapy system may be programmed to selectively collect the fluid properties and provide alerts and/or alarms based on a predetermined order with times designated for each wound dressing.

[00130] After the negative pressure control algorithm 605 proceeds to the dressing-alert algorithms including, for example, the blockage detection algorithm and fluid leak detection algorithm shown generally at 620 in Figure 13B, the algorithm may commence with determining whether the wound pressure (WP) is increasing at 621 after increasing the pump duty cycle (PD) at 616 by a predetermined increment as an output of the wound pressure control 610. If the wound pressure (WP) responds and is increasing, the algorithm may increment an air leak counter at 622 and proceed to the air leak detection algorithm and desiccation detection algorithm at 640. However, if the wound pressure (WP) does not increase, the blockage/leak detection algorithm 620 determines whether the property signals associated with the humidity, i.e., the humidity data, is rising at a relatively low rate within the therapy cavity at 623. If the humidity data is rising at a relatively low rate, the blockage/leak detection algorithm 620 increments a blockage counter 624 and inquires whether the blockage counter is less than a predetermined blockage count threshold at 625 such as, for example, less than three, to determine whether a blockage alert or alarm should be generated. If the blockage counter number is less than the blockage count threshold, the blockage/leak detection algorithm 620 generates a blockage alert at 626 and progresses to log a new set of sensor readings at 650. If the blockage counter number is greater than or equal to the blockage count threshold, the negative pressure control algorithm generates a blockage alarm at 627 and progresses to log a new set of sensor readings at 650.

[00131] If the humidity data is not rising at a relatively low rate at 623, the negative pressure control algorithm inquires whether the humidity data is increasing at a high rate at 628. If the humidity data is not increasing at such a high rate, the blockage/leak detection algorithm 620 increments the air leak counter 622 and proceeds to the air leak detection algorithm and desiccation detection algorithm at 640. However, if the humidity data is increasing above the high rate, the blockage/leak detection algorithm 620 increments or increases a fluid leak counter at 629 and inquires whether the fluid leak counter is less than a predetermined leakage count threshold at 630 such as, for example, less than three. If the fluid leak counter number is not less than the leakage count threshold, alternatively greater than or equal to the leakage count threshold, the blockage/leak detection algorithm 620 generates a fluid leak alarm at 631 and progresses to log a new set of sensor readings at 650. If the fluid leak counter number is less than the leakage count threshold, the blockage/leak detection algorithm 620 checks the dead space detection at 632 that may be associated with the amount of gas or space that may be present in the container of the therapy system such as, for example, the container 112, after collecting liquids in the container. The blockage/leak detection algorithm 620 determines whether there is a dead space detection variance of less than a predetermined value, e.g., 200cc, at 633. If the variance is not less than the predetermined value, i.e., if the variance is greater than the predetermined value, the blockage/leak detection algorithm 620 generates a fluid leak alarm at 631. If the blockage/leak detection algorithm 620 determines that the variance is less than the predetermined value, the blockage/leak detection algorithm 620 generates a canister full alert 667 (not shown in Figure 13 A) and then progresses to log a new set of sensor readings at 650.

[00132] After the negative pressure control algorithm 605 proceeds to the dressing-alert algorithms including, for example, the air leak detection algorithm and desiccation detection algorithm at 640, or a desiccation/leak detection algorithm, shown generally at 640 in Figure 13C, the algorithm may commence by determining at 641 whether the air leak counter at 622 is less than a predetermined air count threshold at 641 such as, for example, less than three, after incrementing the air leak counter as described above. If the air leak counter 641 is less than the air count threshold, the negative pressure control algorithm may generate an air leak alert at 642 and progress to log a new set of sensor readings at 650. If the air leak counter 641 is not less than the air count threshold, alternatively if the air leak counter is greater than or equal to the air count threshold, the desiccation/leak detection algorithm 640 may generate an air leak alarm at 643 and proceed to inquire whether the humidity is less than about a predetermined internal humidity value at 644. More specifically, if the humidity within the therapy cavity of the sensing pad is less than a percentage value of the ambient humidity such as, for example, a percentage value of 25%, the desiccation/leak detection algorithm 640 may generate a desiccation alert at 645 and proceed to log new set of sensor readings at 650. Alternatively, if the humidity within the therapy cavity of the sensing pad is greater than a humidity percentage of 25%, for example, the desiccation/leak detection algorithm 640 would not generate a desiccation alert, but rather would proceed to log new set of sensor readings at 650.

[00133] Referring back to Figure 11, a new set of property signals indicative of the sensor properties may be logged at 650 into the controller of the therapy system as a result of the alerts, alarms, and other events described above with respect to the negative pressure control algorithm 605 including the wound pressure control 610, the blockage detection and fluid leak detection algorithms 620, and the air leak detection algorithm and desiccation detection algorithm at 640. Logging these property signals along with contemporaneous readings of the wound pressure (WP), the pump pressure (PP), and the pump duty cycle (PD) generates sets of property data that may include humidity data, temperature data, and pH data being provided by the processing element such as, for example, the sensor assembly 425 in addition to the pressure data, duty cycle data, and other data that might be available from other sensors in the therapy system 100. Such other sensors also may be coupled to the controller or other distribution components in the therapy system. In some embodiments, the negative pressure control algorithm 605 may be configured to assess the pH data at 652, the humidity data at 654, and the temperature data at 656, and use such data to assess the status of wound health of the tissue site at 658, and further configured to return to the wound pressure control 610 after the assessments have been completed. In some embodiments, the assessments may include an analysis of whether the data is increasing or decreasing and how rapidly the data may be increasing or decreasing. In some embodiments, the assessments may further include an analysis of whether the data may increase or decrease and how rapidly that data may fluctuate in each direction. In some embodiments, the assessment may further include a determination that the relevant data is simply not affected. [00134] The assessments of the pH data, the humidity data, and the temperature data along with contemporaneous wound pressure (WP) data, pump pressure (PP) data, and the pump duty cycle (PD) data may be utilized to determine how the flow characteristics of the therapy system 100 may be affected by a blockage, a fluid leak, an air leak, or desiccation within the system including the sensor pad or dressing interface 400. Referring more specifically to Table 1, the flow characteristics may include a blockage state condition within the therapy system that may be identified by the assessment of the pH data, the humidity data, and the temperature data along with contemporaneous wound pressure (WP) data, pump pressure (PP) data, and the pump duty cycle (PD) data.

Table 1

[00135] For example, a blockage state condition may be identified in the system (e.g., a substance blocking a tube or a kink in the tube) when the pump pressure (PP) data increases and the pump duty cycle (PD) data increases. In some embodiments, the blockage state condition may be identified further if the wound pressure (WP) data slowly decreases. In yet other embodiments, the blockage state condition may be identified further if the humidity data slowly increases, especially if the wound dressing is saturated with fluids. In yet other embodiments, the blockage state condition may be identified further if the temperature data slowly increases. In still other embodiments, the blockage state condition may be identified further when the pH data is not affected. Referring to Figure 14 as an example, a graph is shown illustrating test results using the dressing interface 400 for the detection of blockages based on the assessment of humidity data and wound pressure over time generated by the negative pressure control algorithm 605 of Figure 11. The wound pressure (WP) being applied at the tissue site is set as a target pressure (TP) of 125 mmHg. As can be seen, a blockage state condition is identified at approximately 1.50 minutes when the wound pressure (WP) 701 begins to decrease and the dressing humidity 702 slowly increases over the ambient humidity 703 as described above. In some embodiments, the negative pressure control algorithm 605 may generate a command to provide an alarm 661 and shut down the pump 104, for example, until the blockage can be removed. When the blockage is removed at 3.67 minutes, the wound pressure (WP) returns to the target pressure (TP) and the dressing humidity converges back to the ambient humidity. [00136] Still referring more specifically to Table 1, the flow characteristics may include a fluid leak state within the therapy system that also may be identified by the assessment of the pH data, the humidity data, and the temperature data along with contemporaneous wound pressure (WP) data, pump pressure (PP) data, and the pump duty cycle (PD) data. For example, a fluid leak state may be identified in the wound dressing if the pump duty cycle (PD) data and the pump pressure (PP) data increase depending on the severity of a fluid bolus trapped in the wound dressing. The pump pressure (PP) data may increase for only a short period of time. In some embodiments, the fluid leak state may be identified further if the wound pressure (WP) data decreases, but will typically track with the pump pressure (PP) data. In yet other embodiments, the fluid leak state may be identified further if the humidity data increases as a result of higher exudates or blood volumes collecting at the tissue site. The temperature data may also increase in a corresponding fashion. In still other embodiments, the fluid leak state may be identified further when the pH data is not affected. Referring to Figure 15 as an example, a graph is shown illustrating test results using the dressing interface 400 for the detection of fluid leaks based on the assessment of humidity data and wound pressure data over time generated by the negative pressure control algorithm of Figure 11. The wound pressure (WP) being applied at the tissue site is set as a target pressure (TP) of 125 mmHg. A bolus of 60cc of simulated wound fluid with a viscosity of about 16cP was rapidly introduced into the wound dressing. As can be seen, a fluid leak state is identified at approximately 0.50 minutes when the wound pressure (WP) 711 begins to decrease and the dressing humidity 712 slowly increases over the ambient humidity 713 as described above. In some embodiments, the negative pressure control algorithm 605 may generate a command to provide an alarm 662 and shut down the pump 104, for example, until the fluid leak can be corrected. Clearly, such assessment facilitates the detection of liquid boluses or potentially adverse events such as a blood vessel that bursts, so that a caregiver may be alerted to a potentially dangerous situation so that a timely intervention is possible.

[00137] Referring more specifically to Table 2, the flow characteristics may include an air leak state within the therapy system that may be identified by the assessment of the pH data, the humidity data, and the temperature data along with contemporaneous wound pressure (WP) data, pump pressure (PP) data, and the pump duty cycle (PD) data.

Table 2

[00138] For example, an air leak state within the therapy system that may be identified when the pump duty cycle (PD) data increases proportionally with the severity of the leak, and wherein the pump pressure (PP) data may increase or nonresponsive to an increase in the pump duty cycle (PD) data again depending on the severity of the leak. The air leak may be sufficiently severe to require an increase in both the pump duty cycle (PD) and the pump pressure (PP). In some embodiments, the air leak state may be identified further if the wound pressure (WP) begins to decrease proportionally with the severity of the leak, but will track with the pump pressure (PP). In yet other embodiments, the air leak state may be identified further if the humidity data changes rapidly depending upon the environmental humidity measured by the system and the saturation level of the wound dressing. For example, if the air is drier than the saturation level of the wound dressing, then the humidity of the dressing may decrease. The air leak state may also be identified further if the temperature data changes depending on the environmental temperature and the saturation level of the wound dressing. For example, the temperature data will decrease if the environmental temperature is cooler than the temperature at the tissue site. In still other embodiments, the air leak state may be identified further when the pH data is not affected. Referring to Figure 16 as an example, a graph is shown illustrating test results using the dressing interface 400 for the detection of air leaks based on the assessment of humidity data, wound pressure data, and pump pressure data over time generated by the negative pressure control algorithm of Figure 11. The wound pressure (WP) being applied at the tissue site is set as a target pressure (TP) of 125 mmHg. A small leak was introduced into the wound dressing such that the pump pressure (PP) had to be elevated to approximately 140 mmHg in order to maintain a wound pressure (WP) at the target pressure (TP). As can be seen, an air leak state is identified at approximately 0.2 minutes when the wound pressure (WP) 721 decreases and the pump pressure (PP) 722 increases to compensate for the decreasing wound pressure (WP). In some embodiments, the air leak state also may be identified by the dressing humidity 723 which slowly increases to converge with the ambient humidity 724. In this example, the tissue interface was dry, so that the humidity increased with the introduction of the leak (ambient humidity). In other embodiments, the air leak state also may be identified by the dressing humidity 723 which slowly decreases to converge with the ambient humidity 724.

[00139] In some embodiments where the humidity data decreases indicating that the wound is drying out, the negative pressure control algorithm 605 may generate a command to provide an alarm 663 and shut down the pump 104 until the air leak can be corrected. In other embodiments where the humidity does not decrease or is at an acceptable level, the negative pressure control algorithm 605 may generate a command to provide an alarm or an alert 663, but continue providing therapy by increasing the pump duty cycle (PD) to compensate for the air leak. Referring back to Table 1, an air leak state may be distinguished from a fluid leak state because the humidity data will increase in the presence of a fluid leak, but will not increase in the presence of an air leak (although it may fluctuate rapidly). Clearly, such assessment facilitates the detection of air leaks by differentiating them from fluid leaks, so that the therapy system may continue providing negative pressure therapy by increasing the pump duty cycle (PD) to compensate for the air leak rather than discontinuing the therapy being provided.

[00140] Still referring more specifically to Table 2, the flow characteristics may include a desiccation state within the wound dressing that also may be identified by the assessment of the pH data, the humidity data, and the temperature data along with contemporaneous wound pressure (WP) data, pump pressure (PP) data, and the pump duty cycle (PD) data. For example, a desiccation state may be identified if the pump pressure (PP) data and the pump duty cycle (PD) data remain unchanged, unless there is an air leak present which causes a moisture drop. In some embodiments, the desiccation state may be identified further if the wound pressure (WP) the also remains unchanged, unless there is an air leak present. In yet other embodiments, the desiccation state may be identified further if the humidity data decreases longitudinally over time. The humidity data may be tracked and compared to a minimum threshold value to prevent or avoid wound desiccation. The negative pressure control algorithm may be configured to provide an alert and/or an alarm in the event that the humidity data falls below the minimum threshold value. In still other embodiments, the desiccation state may be identified further if the pH data decreases slightly as the tissue site becomes slightly more acidic from drying. The temperature data also may change based on drying and the lack of sufficient exudation of the at the tissue site. Referring to Figure 17 as an example, a graph is shown illustrating test results using the dressing interface 400 for the detection of desiccation conditions based on the assessment of humidity data over time generated by the negative pressure control algorithm of Figure 11. The tissue interface such as, for example, tissue interface 108, was fdled in saturated with simulated wound fluid. After the tissue interface was saturated with the wound fluid, the wound pressure (WP) was set as a target pressure (TP) of 125 mmHg and applied to the tissue interface. As can be seen, a desiccation state may be identified a decreasing dressing humidity 731 compared to the ambient humidity by tracking the humidity data and comparing it to a minimum threshold value as described above. In some embodiments, the negative pressure control algorithm 605 may generate a command to provide an alert 664 and shut down the pump 104, for example, until the desiccation can be corrected.

[00141] The assessments of the pH data at 652, the humidity data at 654, and the temperature data at 656 along with contemporaneous wound pressure (WP) data, pump pressure (PP) data, and the pump duty cycle (PD) data may be utilized to assess the health of the wound at 658 including, for example, the progression of wound healing, i.e., the wound status.

Table 3

[00142] Referring more specifically to Table 3, the wound status may include a determination of the progression of wound healing that may be identified by the assessment of the pH data, the humidity data, and the temperature data along with contemporaneous wound pressure (WP) data, pump pressure (PP) data, and the pump duty cycle (PD) data. For example, a wound healing state may be identified when the pH data changes in response to wound healing regression or progression. For example, in some embodiments, the wound may be considered in a healthy state if the wound fluids have a pH of approximately 7.4 and the pH data indicates that the pH has held at that value over a predetermined time period. In some other embodiments, the wound may be considered in a healthy state if the wound fluids have a pH that stays within a range from about 5.0 to about 8.0 and remains within that range over a predetermined time period. More specifically, if the pH data exceeds 8.0, the wound may be considered to be in a chronic state. Additionally, if the pH data is less than about 6.0, the wound may be considered to be in an inflammatory state. In some embodiments, the wound healing state may be identified when the humidity data and the temperature data both increase or decrease slowly at predetermined rates. For example, if the temperature data indicates that the temperature is increasing, the increasing temperature may be an indication that the wound is infected. Additionally, the wound pressure (WP) or the pump pressure (PP) may critically affect the healing progression or regression. For example, if the pressure is not within the therapeutic range that was prescribed, then the patient is not getting the benefit of the therapy. However, wound progression or regression does not necessarily affect the wound pressure (WP) or the pump pressure (PP). In some embodiments, the negative pressure control algorithm 605 may generate a command to provide an alert 665 and continue providing therapy including, for example, the instillation of fluids that may include medication until the pH returns to an acceptable range.

[00143] Figure 18 is a schematic block diagram illustrating an embodiment of a control algorithm that may comprise a fluid instillation control algorithm that may be utilized when applying the fluid instillation therapy 606 within the tissue treatment method 600, hereinafter referred to as the fluid instillation control algorithm 706. The fluid instillation control algorithm 706 may include the detection of dressing flow characteristics within the system and an assessment of sensor properties based on the property data stored on the controller of the therapy system. Figures 19A-19B show flow charts illustrating various methods of some embodiments that may be configured to operate within the fluid instillation control algorithm 706 of Figure 18. The fluid instillation therapy algorithm 706 may commence by initializing the therapy settings at 603 including logging the baseline readings of the sensors at 703 and setting the initial values of the property signals provided by the sensors. In some embodiments, the property signals may be sent to the processing element of the dressing interface and ultimately to the controller of the therapy system as indicated for processing and assessment.

[00144] A tissue interface such as the tissue interface 108 may be placed within, over, on, or otherwise proximate a tissue site as described above, and may include an accelerometer or other device for determining whether the sensors within the dressing interface are properly oriented at the tissue site. The fluid instillation control algorithm 706 may include a dressing orientation process at 708 that processes data from the accelerometer to determine whether sensors in the dressing interface are correctly oriented with respect to the tissue interface at the tissue site. If the sensors are not correctly oriented (NO), the fluid instillation control algorithm 706 in some embodiments may proceed to a dressing -fill assist subroutine at 710 shown more specifically in Figure 19A. When the dressing-fill assist subroutine is completed, the sensor readings may be logged and assessed at 720 along with a measurement of the amount of fluid dispensed to the tissue interface, i.e., the dispensed fill volume, as a result of the dressing-fill assist subroutine. After the sensor readings and the dispensed fill volume have been logged and assessed, the fluid instillation control algorithm 706 may further comprise providing wound pressure alerts at 721 similar to those described above.

[00145] Referring back to 708, if the tissue interface is correctly oriented (YES), the fluid instillation control algorithm 706 in some embodiments may proceed to a pump control routine the compares the relative dressing humidity to a target humidity, and then provides commands to start or stop the instillation pump depending on the results of the comparison. More specifically, the pump control routine may compare the relative dressing humidity to the target humidity at 722 and stop the instillation pump at 723 (YES) if the relative dressing humidity exceeds the target humidity. After the instillation pump has been stopped at 723, the sensor readings and the dispensed fill volume may be logged and assessed at 720 and wound pressure alerts may be provided at 721. The pump control routine may include a redundant check of the role dressing humidity in comparison to the target humidity at 724 and stop the instillation pump at 725 (NO) if the relative dressing humidity is less than the target humidity. After the instillation pump has been stopped at 725, the sensor readings and the dispensed fill volume may be logged and assessed at 720 and wound pressure alerts may be provided at 721. Thus, if the relative dressing humidity is not greater than the target humidity at 722 and less than the target humidity at 724, then the fluid instillation control algorithm 706 in some embodiments may proceed to dressing-alert algorithms including, for example, a blockage detection algorithm and fluid leak detection algorithm shown generally at 730 shown more specifically in Figure 19B. After either a blockage or dressing leak has been identified, the fluid instillation control algorithm 706 in some embodiments may log the sensor readings at 750 and loop back to 722 for further comparisons of the relative dressing humidity to the target humidity. However, if the relative dressing humidity is greater than the target humidity at 722 and not less than the target humidity at 724, the pump may be stopped to log and assess the sensor readings and the dispensed volume.

[00146] After the fluid instillation control algorithm 706 proceeds to the dressing-alert algorithms including, for example, the blockage detection algorithm and fluid leak detection algorithm shown generally at 730 in Figure 19A, the algorithm may provide a command to continue operating the instillation pump at 731 and proceed to determine whether the relative dressing humidity is increasing at 732. If the relative dressing humidity is not increasing (NO), the fluid instillation control algorithm 706 may proceed to determine whether the duty cycle (ID) of the instillation pump is increasing at 733. The algorithm may proceed to implement the fluid leak detection algorithm if the duty cycle (ID) is not increasing (NO), or to implement the blockage detection algorithm if the duty cycle (ID) is increasing (YES). When the fluid instillation algorithm proceeds with the blockage detection algorithm, the algorithm may increment a blockage counter at 734 and proceed to determine whether the blockage counter is less than a predetermined blockage count threshold at 735 such as, for example, less than three increments to determine whether a blockage alert or alarm should be generated. If the blockage counter is less than the blockage count threshold, the blockage detection algorithm may generate a blockage alert at 736 and proceed to log a new set of sensor readings at 750, e.g., pH, temperature, and humidity readings. If the blockage counter number is greater than or equal to the blockage count threshold, the blockage detection algorithm may generate a blockage alarm at 737 and proceed to log a new set of sensor readings at 750. The blockage detection algorithm may then loop back to check the relative dressing humidity with respect to the target humidity at 722 as described above.

[00147] As indicated above, the fluid instillation control algorithm may proceed to implement the fluid leak detection algorithm if the duty cycle (ID) of the instillation pump is not increasing (NO) at 733 and proceed to increment a leakage counter at 738. The leakage detection algorithm may then proceed to determine whether the leakage counter is less than a predetermined leakage count threshold at 740 such as, for example, less than three increments to determine whether a leakage alert or alarm should be generated. If the fluid leak counter is not less than the leakage count threshold, alternatively greater than or equal to the leakage count threshold, the leak detection algorithm may generate a fluid leak alarm at 741 and proceed to log a new set of sensor readings at 750. However, if the fluid leak counter number is less than the leakage count threshold, the leak detection algorithm may generate a dressing leak alert at 742 and proceed to check a dead space detection algorithm at 743 that may be associated with the amount of gas or space that may be present in the tissue interface of the dressing such as, for example, the tissue interface 108 of the dressing 102 after instilling liquids into the tissue interface. The leak detection algorithm may determine whether there is a dead space detection variance of less than a predetermined value, e.g., 200cc, at 744. If the variance is not less than the predetermined value, i.e., if the variance is greater than the predetermined value, the leak detection algorithm may generate a fluid leak alarm at 741. If the leak detection algorithm may determine that the variance is less than the predetermined value, the leak detection algorithm may generate a canister-full alert 667 (not shown in Figure 19A) and then proceed to log a new set of sensor readings at 750. Returning back to the decision at 732 of the fluid instillation control algorithm, the algorithm proceeds to log a new set of sensor readings at 750 if the relative dressing humidity is increasing and then loops back to check the relative dressing humidity with respect to the target humidity at 722 as described above.

[00148] Referring back to Figure 18, the fluid instillation control algorithm 706 may further comprise a fill assist algorithm 710 that may facilitate determining whether the tissue interface has been instilled with a volume of fluids desired for the instillation therapy, i.e., a desired fill volume. Referring more specifically to Figure 19B, the fill assist algorithm 710 may comprise a dead space detection algorithm 711 that may be similar to the dead space detection algorithm 743 described above. The fill assist algorithm 710 may then proceed to provide a command to a controller to evacuate a therapy cavity of a dressing interface such as, for example, the controller 110 evacuating the therapy cavity 403 of the dressing interface 400, to a negative pressure sufficient to commence instillation of the fluids at 712. For example, a negative pressure of about 25 mmHg, which is well below the negative pressure therapy level of negative pressure, may be applied to the therapy cavity to commence instillation of the fluids. The negative pressure may be provided by the suction of a negative pressure pump such as, for example, the negative pressure pump 104, as described in more detail above.

[00149] In some embodiments, providing this suction may be sufficient for instilling fluid into the therapy cavity. In other embodiments, an instillation pump such as, for example, the instillation pump 116, may be used in conjunction with the suction to commence instillation. For example, the instillation pump may provide a positive force to instill the fluids into the therapy cavity as shown at 713 and may be supplemented by continuing to provide negative pressure from the negative pressure pump . The fill assist algorithm 710 may also include a pressure check algorithm at 714 for determining whether pressure changes within the therapy cavity are within an acceptable range, while instilling fluids into the therapy cavity and allowing those fluids to soak for a desirable so time. If the pressure measured is not within the acceptable range (NO), the fill assist algorithm 710 may generate a dressing leak alarm at 741. However, if the pressure measured is within the acceptable range (YES), the fill assist algorithm 710 may provide a command to a controller to generate a command to open a pressure relief valve at 715 such as, for example, the controller 110 generating a command to the regulator 118 as described above, in order to further evacuate gases from the therapy cavity and draw liquids into the therapy cavity. The controller may be programmed to open the pressure relief valve for a fill period sufficient to provide the therapy cavity and the tissue interface with a desired fill volume. The fill assist algorithm 710 may also continue providing fill assist at 716 by refilling the therapy cavity until previous fill volumes are achieved for another cycle of instillation therapy. Whenever the desired fill volume or fill volumes are achieved, the fill assist algorithm 710 may proceed back to the fluid instillation control algorithm 706 so that the sensor readings may be logged and assessed at 720 along with a measurement of the amount of fluid dispensed to the tissue interface, i.e., the dispensed fill volume. After the sensor readings and the dispensed fill volume have been logged and assessed, the fluid instillation control algorithm 706 may continue by providing wound pressure alerts at 721 similar to those described above.

[00150] Referring back to Figure 18, a new set of sensor readings indicative of the sensor properties and dispensed volumes may be logged at 720 into the controller of the therapy system as a result of the alerts, alarms, and other events described above with respect to the fluid instillation control algorithm 706 including the dressing orientation control 708, the fill assist algorithm 710, and the blockage detection and fluid leak detection algorithms 730. Logging these property signals along with contemporaneous readings of the wound pressure (WP), the instillation pump pressure (IP), and the instillation pump duty cycle (ID) generates sets of property data that may include humidity data, temperature data, and pH data being provided by the processing element such as, for example, the sensor assembly 425, in addition to the pressure data, duty cycle data, and other data that might be available from other sensors in the therapy system 100. Such other sensors also may be coupled to the controller or other distribution components in the therapy system. For example, some embodiments may include an occlusion sensor (not shown), such as the fluid connections located in the therapy device shown in Figure 1, that independently checks the possibility of a blockage or kink in the conduits or tubing coupled to the dressing interface. In some embodiments, the fluid instillation control algorithm 706 may be configured to assess the pH data, the humidity data, the temperature data, and the dispensed volume of fluids, and then use such assessment data to evaluate the status of wound health of the tissue site at 721. The fluid instillation control algorithm 706 may be configured further to return to the wound pressure control algorithm 605 after such assessments have been completed. In some embodiments, the assessments may include an analysis of whether the data is increasing or decreasing and how rapidly the data may be increasing or decreasing. In some embodiments, the assessment may further include a determination that the relevant data is simply not affected

[00151] The assessments of the pH data, the humidity data, the temperature data, and the dispensed volume data, along with contemporaneous wound pressure (WP) data, instillation pump pressure (IP) data, and the instillation pump duty cycle (ID) data may be utilized to determine how the flow characteristics of the therapy system 100 may be affected by a blockage, a fluid leak, or a full canister within the system including the sensor pad or dressing interface 400. Referring more specifically to Table 4 and Figure 20, the flow characteristics may include a blockage state condition within the therapy system that may be identified by the assessment of the humidity data and the temperature data of the tissue site or the wound, along with contemporaneous wound pressure (WP) data, instillation pump pressure (IP) data, the instillation pump duty cycle (ID) data, and the occlusion sensor.

Table 4

[00152] For example, a blockage state condition may be identified in the system (e.g., a substance blocking a tube or a kink in the tube) when the instillation pump pressure (IP) data increases and the instillation pump duty cycle (ID) data increases. In some embodiments, the blockage state condition may be identified further if the relative dressing humidity does not increase toward a target humidity such as, for example, a target humidity threshold which in some embodiments corresponds to a condition of the tissue interface being instilled to a desired fill volume . Figure 20 is a graph illustrating an instillation response curve 760 including data associated with the relative humidity percentage of a dressing in response to the fluid instillation control algorithm of Figure 18. The graph includes, for example, a target humidity threshold 762 that is about 90% which may be determined to be an indication that the tissue interface is fully saturated with fluids as a result of instilling the desired fill volume. In this example, the relative humidity data is increasing at 761 of the response curve 760 toward the target humidity threshold 762 so that a blockage condition might not exist apart from other information. In yet other embodiments, the blockage state condition may be identified further if the temperature data does not decrease. For example, in some embodiments the temperature data does not decrease because the fluid simply does not reach into the tissue interface. Normally, the body temperature of the patient is warmer than the temperature of the fluids being instilled so that the temperature of the instillation fluid should drop if the fluid reached the tissue interface. In some other embodiments, the blockage state condition may be identified further if the wound pressure (WP) increases. In still other embodiments, the blockage state condition may be identified further when the occlusion sensor located in the fluid conduits of the therapy device is tripped. In some embodiments, the fluid instillation control algorithm 706 may generate a command to provide an alarm 661 and shut down the pump 116, for example, until the blockage can be removed and the relative dressing humidity begins to increase toward the target humidity threshold such as, for example, toward 90% as shown in Figure 20.

[00153] Still referring more specifically to Table 4, the flow characteristics may include a fluid leak state within the therapy system that also may be identified by the assessment of the humidity data and the temperature data, along with contemporaneous wound pressure (WP) data, instillation pump pressure (IP) data, the instillation pump duty cycle (ID) data, and the occlusion sensor. For example, a fluid leakage state may be identified in the wound dressing if the instillation pump duty cycle (ID) data does not increase. This may result from a fluid bolus trapped in the wound dressing that does not fill the therapeutic cavity, a closed volume, resulting in the lack of a back pressure that should have resulted from filling the therapeutic cavity. In some embodiments, the fluid leak state may be identified further if the humidity data increases, but does not increase fully toward the target threshold humidity of 90% to satisfy an assessment that the tissue interface is full. In still other embodiments, the fluid leak state may be identified further if the temperature data changes depending on the size of the leak. For example, if the body temperature is warmer than the temperature of the instillation fluid, then the temperature of the instillation fluid will decrease provided that the fluid does contact the tissue interface before leaking out of the dressing. In some embodiments, the fluid instillation control algorithm 706 may generate a command to provide an alarm 662 and shut down the pump 116, for example, until the fluid leak can be corrected. Clearly, such assessment facilitates the detection of liquid boluses or potentially adverse events such as a blood vessel that bursts with the addition of instillation fluid in a fixed volume, so that a caregiver may be alerted to a potentially dangerous situation and/or the controller can quickly shut down the pump 116.

[00154] Still referring to Table 4, the flow characteristics may include a dressing fill status for the therapy system to assist a caregiver by the assessment of the humidity data and the temperature data, along with contemporaneous wound pressure (WP) data. For example, a dressing fill status may be identified in the wound dressing if the humidity data increases to the target threshold humidity such as, for example, toward the 90% humidity as shown in Figure 20 indicating that the therapy cavity and/or the tissue interface is saturated with the instillation liquid as metered out by desired fill volume. In some embodiments, the fluid instillation control algorithm 706 may generate a command to provide a canister full alert 667 and/or shut down the pump 116, for example, because the relative dressing humidity increased to a target humidity threshold such as, for example, 90% to detect a fully saturated dressing at a predetermined desired fill volume of about 38 ml at 764. Once the dressing is fully saturated to this predetermined value, the relative dressing humidity remains substantially constant as shown by the flat portion 763 of the response curve 760. In still other embodiments, a dressing fill status may be identified if the temperature decreases as instillation fluid is introduced into the dressing. For example, if the body temperature is warmer than the temperature of the instillation fluid, then the temperature of the instillation fluid will decrease provided that the fluid does contact the tissue interface before leaking out of the dressing. In yet other embodiments, a dressing fill status may be identified if the wound pressure (WP) increases to a pressure slightly higher than the ambient pressure, or if the wound pressure (WP) does not increase or decrease after the dressing is saturated with the instillation fluids. Such assessment facilitates the identification of a dressing fill status to assist a caregiver’s visual monitoring of the dressing so that the caregiver may be alerted to a potentially dangerous situation and the controller can quickly shut down the relation pump 116 after the desired fill volume has been achieved.

[00155] Figure 21 is a block diagram of a wireless architecture of another embodiment of a sensor assembly, sensor assembly 2125, which may be substantially similar to the sensor assembly 425. For example, the sensor assembly 2125 may be coupled to the sensors including the pressure sensor 416, the temperature and humidity sensor 418, and the pH sensor 420, in the therapy cavity 403 and be configured to read the sensors in substantially the same way as the sensor assembly 425. The wireless module architecture comprises a core module 2105 implemented on circuit board 2132 of sensor assembly 2125. The core module 2105 comprises a system-on-a-chip (SoC) module 2110 that includes a central processor unit (CPU) 2115 and a Bluetooth low energy (BLE) transceiver (X-CVR) 2120 with built-in analog front end. By way of example, SoC module 2110 may be a Nordic© nRF51 series SoC or a Rigado© BMD-200 SoC. Both of these SoC devices are flexible, mu lti-protocol, wireless circuits for ultra-low power wireless applications, such as Bluetooth low energy (BLE) applications. Both SoC devices include processors, Bluetooth transceivers, antennas, and analog front ends. Those skilled in the art will understand that other types of SoC modules may be used and may communicate according to other wireless protocols, including WiFi, cellular, and the like.

[00156] The core module 2105 further comprises a general purpose input-output (GPIO) bus 2155, the pressure sensor 416, the temperature/humidity sensor 418, the pH sensor 420, a light-emitting diode (LED) 2130, and at least one peripheral device 2135. The GPIO bus 2155 comprises an internal bus 2155A that is part of SoC module 2110 and an external bus 2155B that is implemented on circuit board 2132 outside of SoC module 2110. Bus 2155A and bus 2155B may be, for example, an inter- integrated circuit (I²C) connection bus used for coupling lower speed peripheral integrated circuits to SoC module 2110 for short-distance, intra-board communication. The I²C connection bus is a de facto standard interface protocol for many currently available sensors. Thus, internal bus 2155 A couples SoC module 2110 to the pressure sensor 416, the temperature/humidity sensor 418, the pH sensor 420, a light emitting diode (LED) indicator 2130, and at least one peripheral device 2135. Similarly, external bus 2155B couples SoC module 2110 and core module 2105 to additional peripherals 2160 and 2165 that are in expansion slots or daughter boards external to core module 2105.

[00157] In an exemplary embodiment, the pressure sensor 416 may comprise a TE Connectivity© 1620 sensor, an Amphenol© NPC-120 sensor, or a Merit© BP0002 sensor. Similarly, the temperature/humidity sensor 418 may comprise a TE Connectivity© HTU21D sensor or a Sensirion© SHT31-DIS-F sensor. Finally, the pH sensor 420 may comprise a direct input passive electro-chemical sensor that measures subtle changes in voltage potential and is manufacture by screen printing electrodes onto a polyamide or equivalent fdm substrate. Sensor assembly 2125 may comprise an activation switch or a plastic tab insulating battery 424 from creating a power connection. When the plastic tab is pullet to activate, LED indicator 430 may illuminate once sensor assembly 2125 is powered up and BLE transceiver 2120 has paired with an external control device used by an operator.

[00158] The core module 2105 further comprises a high-speed bus 2150 and USB 3.0 type-C microconnector 2140. Bus 2150 comprises an internal bus 2150A within SoC module 2110 and an external bus 2150B that is implemented on circuit board 2132 outside of SoC module 2110. Bus 2150 provides 2-way communications and may be used for connection, communication, and power supply between sensor assembly 2125 and add-on devices, such as WiFi, 3G, 4G or 5G GSM cellular communications, Bluetooth communications modules, additional Serial Peripheral Interface bus (SPI) connections, graphical user interface (GUI) or pointing devices, digital cameras, daughter boards with additional electro-chemical sensors, and additional power sources for the addition of therapy supply/control.

[00159] By way of example, bus 2150 may couple core module 2105 to USB 3.0 daughter boards 2170 and 2180. Daughter board 2170 couples SoC module 2110 to an exemplary serial device 2175. Daughter board 2180 couples SoC module 2110 to a plurality of expansion devices, including cellular transceiver 2181, display/GUI device 2182, WiFi transceiver 2183, firmware updating device 2184, and secondary sensor 2185. A single USB 3.0 port is able to permit the connection of at least 127 separate devices through a system of hubs.

[00160] Core module 2105 may be connected to a range of external interfaces and extended systems but provides key features in such a system. It is also intended that these external devices may not be just “data-out” systems, but may facilitate two-way communications such that control (or limited control) of the therapy system may be made by an operator via the peripherals. These peripherals may include: i) a display or user interface, such as a LCD, touch screen, LED membrane; ii) a cellular (3G, 4G, 5G) mobile communication module to allow the system to communicate via a mobile phone network with, for example, a smartphone or the like, iii) a GPS circuit for tracking the operator, iv) movement sensors such as accelerometers (for measuring patient activity levels or patient compliance); v) VoC sensors or other sensors of biologic activity or byproducts of biological processes which may indicate the presence of a disease state; and vi) WiFi communications to a facility or home network.

[00161] It is anticipated that core module 2105 may not have sufficient power capacity to run all but the most basic peripheral systems. Thus, any external peripherals may require further power supply and power management which can be managed by an appropriate power module connected via USB to the core module 2105. In such a scenario, the core module 2105 would derive power from the peripheral. By way of example, USB 3.0 microconnector 2140 may be coupled to communication port 412 in Figure 5B and receive power from an external peripheral device. Furthermore, it is considered advantageous to restrict software and firmware upgrades to core module 2105 to a hard-wired USB connection (via firmware device 2184) and to prohibit access to the system core from the peripherals. This should prevent external access to the core system, which could prove problematic if accessed by an unauthorized external agent.

[00162] Figure 22 is a first wireless network topology for controlling the therapy system according to an exemplary embodiment of the disclosure. In Figure 22, dressing interface 400 is controlled by and in communication with therapy controller 2210. Therapy controller 2210 is similar to and performs the same functions as controller 110 in Figure 1. Dressing interface 400 is similar to and performs the same functions as dressing 102 in Figure 1. For simplicity, the remaining components of Figure 1 are omitted.

[00163] The therapy controller 2210 comprises a wireless transceiver (WT) 2211 for communicating with the core module 2105 on sensor assembly 2125 in dressing interface 400. In an advantageous embodiment, WT 2211 communicates with core module 2105 on sensor assembly 2125 according to the Bluetooth low energy (BLE) protocol. Alternatively, therapy controller 2210 may use a wireline, such as a USB cable, coupled to communication port 412 to communicate with dressing interface 400. In such an embodiment, power may be supplied from the therapy controller 2210 to dressing interface 400 via the USB cable. Therapy controller 2210 further comprises a wireline interface, such as input-output (I/O) interface 2212, to communicate with an external IP network 2205, such as the Internet. By way of example and without limitation, I/O interface 2212 may be coupled to an Ethernet cable 2206. Because of the use of a short range wireless protocol (i.e., BLE) or a USB cable, it will be understood that dressing interface 400 and therapy controller 2210 may be co-located with each other.

[00164] As described above in Figures 1-20, therapy controller 2210 controls the operation of dressing interface 400 by performing negative pressure would therapy (NPWT) and instillation therapy to the wound site. Therapy controller 2210 receives from core module 2105 the sensor data readings from pressure sensor 416, the temperature/humidity sensor 418, the pH sensor 420, and from other peripherals that may be coupled to core module 2105 on sensor assembly 2125 in dressing interface 400.

[00165] Therapy controller 2210 may also be in communication via IP network 2205 with a remote monitor 2220 that is more remotely located, such as in another room, another building, of another city. Remote monitor 2220 comprises a wireline interface, such as input-output (I/O) interface 2221 , configured to communicate with the IP network 2205. By way of example and without limitation, I/O interface 2221 may be coupled to an Ethernet cable 2207. Remote monitor 2220 may also be coupled to a storage device 2230 that stores the sensor readings that are captured and logged by dressing interface 400 and therapy controller 2210.

[00166] The network topology in Figure 22 enables the dressing interface 400 to be controlled directly by therapy controller 2210 and also remotely by remote monitor 2220. Furthermore, if a display/GUI device 2182 is coupled to core module 2105, the operator may also control and/or interact with dressing interface 400 and therapy controller 2210 directly via the display/GUI device 2182.

[00167] Figure 23 is a second wireless network topology for controlling the therapy system according to an exemplary embodiment of the disclosure. In Figure 23, dressing interface 400 is controlled by and in communication with therapy controller 2310 via IP network 2305 using wireless communication links. In this embodiment, while the air pressure and fluid components in Figure 1 may still be co-located with dressing interface 400, therapy controller 2310 may be more remotely located, such as in another room or another building. The therapy controller 2310 comprises a wireless transceiver (WT) 2311 for communicating with the IP network 2305. In an advantageous embodiment, both core module 2105 and WT 2311 communicates with IP network 2305 according to the WiFi protocol. In such an embodiment, core module 2105 on sensor assembly 2125 may be coupled to a WiFi transceiver 2183 in sensor assembly 2125. It will be understood by those skilled in the art that IP network 2305 may include cellular base stations or similar facilities capable of supporting cellular communication links, such as 3G, 4G, or 5G GSM cellular communication links.

[00168] Therapy controller 2310 may also be in communication with a remote monitor 2320 that may be collocated with therapy controller 2310 or may be more remotely located, such as in another room, another building, or another city. The therapy controller 2310 comprises a wireline interface, such as input-output (I/O) interface 2312, configured to communicate with an input-output (I/O) interface 2321 in remote monitor 2320. By way of example and without limitation, I/O interfaces 2312 and 2321 may be coupled via an Ethernet cable 2315. Remote monitor 2320 may also be coupled to a storage device 2330 that stores the sensor readings that are captured and logged by dressing interface 400 and therapy controller 2310.

[00169] Figure 24 is a third wireless network topology for controlling the therapy system according to an exemplary embodiment of the disclosure. In Figure 24, dressing interface 400, therapy controller 2410, and remote monitor 2420 are all remotely located with respect to each other and communicate via wireless links to IP network 2405. It will be understood by those skilled in the art that IP network 2405 may include cellular base stations or similar facilities capable of supporting cellular communication links, such as 3G, 4G, or 5G GSM cellular communication links.

[00170] The therapy controller 2410 comprises a wireless transceiver 2411 that may be, for example, a WiFi transceiver or a cellular transceiver. Similarly, the remote monitor 2420 comprises a wireless transceiver 2421 that may be, for example, a WiFi transceiver or a cellular transceiver. Fikewise, core module 2105 on sensor assembly 2125 may communicate with IP network 2405 using a WiFi link or a cellular link. In such an embodiment, core module 2105 may be coupled to a WiFi transceiver 2183 or may be coupled to cellular transceiver 2181, or both, in sensor assembly 2125. Remote monitor 2420 may also be coupled to a storage device 2430 that stores the sensor readings that are captured and logged by dressing interface 400 and therapy controller 2410.

[00171] Figure 25 is a method 2500 for wirelessly controlling the dressing interface 400 and the therapy system according to an exemplary embodiment of the disclosure. Initially, dressing interface 400 is powered up at 2505. This may be performed by using an activation switch or removing an insulating tab from battery 424. Alternatively, power may be applied by port 412 from an external source. Once power is applied, sensor assembly 2125 is initialized at 2510 and sets up a communication link (e.g., BFE, WiFi, cellular) to the therapy controller 2210, 2310, or 2410 in any of Figures 22-24. Once a communication link is successfully established, the core module 2105 on sensor assembly 2125 illuminates the FED indicator 2130 to provide a visual indicator to the operator that the dressing interface 400 is ready to perform therapy operations.

[00172] Under the direction of the operator of the therapy controller, the core module 2105 begins to capture sensor data in dressing IF 400 at 2520. The core module 2105 then transmits the sensor data to therapy controller 2210, 2310, or 2410 and may optionally receive operator inputs and display operator information at 2525. Next, at 2530, dressing interface 400 and the other components of Figure 1 perform NPWT therapy and instillation therapy as described above in Figures 1-20 under control of therapy controller 2210, 2310, 2410 and/or the operator. Throughout such NPWT and instillation therapy operations, remote monitor 2202, 2320, 2420 may log sensor data in storage 2230, 2330, 2430. The therapy system then continues to capture sensor and perform NPWT and instillation therapy operations until a predetermined threshold value is reached or predetermined time period has elapsed. [00173] One of the advantages of the core module 2105 described above is that, on its own, it covers at least 80% of the likely wireless communication needs of different types of dressing interfaces 400, particularly for low-end therapy systems and therapy peripherals. By the addition of generic peripheral modules, it is possible to configure the core module 2105 to be able to meet quickly the wireless needs of any other future product. By populating only the components needed for a given application, it is possible to reduce the cost to the point that having the wireless capability in every device is attainable. Key to achieving this is to choose components and modular connections which do not consume needless space and power.

[00174] In an advantageous embodiment of the present disclosure, the therapy controllers 2210, 2310, or 2410 in Figures 22-24 are configured to automatically detect and identify a plurality of different types of dressing interfaces 400. Based on the identification of the dressing interface 400, the therapy controllers 2210, 2310, or 2410 are further configured to select the correct therapy protocol(s) and operating parameters for the identified dressing interface. This prevents the operator from selecting an inappropriate therapy for a specific dressing interface 400, thereby reducing potential harm to a patient.

[00175] Figure 26 is a method for wirelessly controlling the dressing interface and the therapy system according to an exemplary embodiment of the disclosure. In Figure 26, therapy controller 2610 is similar to any one of therapy controllers 2210, 2310, or 2410. In the specific embodiment in Figure 26, therapy controller 2610 is implemented in the form of a tablet device, such as an iPad tablet or an Android tablet. However, this is by way of illustration only and should not be construed to limit the scope of the disclosure. In alternate embodiments, therapy controller 2610 may be an embedded controller in therapy device 100.

[00176] Therapy controller 2610 comprises a product detection circuit that detects and identifies dressing interface 400, either automatically or in response to a user input command on the touch screen of therapy controller 2610. According to the principles of the present disclosure, each dressing interface 400 comprises one or more types of product identifiers 499 that are printed, adhered or otherwise attached to the housing 401 of the dressing interface 400. By way of example and not limitation, the product detection circuit in therapy controller 2610 may be a near-field communication (NFC) transceiver that detects and identifies a near-field communication (NFC) tag 499A. Alternatively, the product detection circuit in therapy controller 2610 may be an RFID transceiver that detects and identifies an RFID tag (passive or active) 499B. In still another embodiment, the product detection circuit in therapy controller 2610 may be a camera that detects and identifies a Q code 499C or a bar code 499D, or both.

[00177] The therapy controller 2610 is simply brought within close proximity of the product identifier 499 in order to automatically read the product and model information and thereby select, for example, the proper graphical user interface (GUI) to allow an operator to follow the correct therapy protocol(s) and operating parameters for dressing interface 400. If the therapy controller 2610 is an embedded controller in therapy device 100, the dressing interface 400 may be brought within close proximity of the therapy controller 2610 to enable the therapy controller 2610 to read the product and model information automatically.

[00178] Figure 27 is a block diagram of the wireless therapy controller 2610 according to an exemplary embodiment of the disclosure. The therapy controller 2610 comprises the conventional components of a tablet device including a cellular transceiver (as described above). In an exemplary embodiment, the cellular transceiver includes an antenna 2705, an RF front-end block 2710, a digital to analog converter/analog to digital converter (DAC/ADC) block 2715, and a baseband processing and audio processing block 2720, which may typically be implemented as a digital signal processor (DSP). The therapy controller 2610 further comprises a central processing unit (CPU) 2725, a memory 2730, an RFID/NFC transceiver 2735, a Bluetooth (BT) transceiver 2740, a microphone (MIC) 2745, a speaker 2750, a display 2755, which includes a integral touchscreen 2760, a camera 2765, a WiFi transceiver 2770, and a USB connector 2775. In an alternate embodiment, a physical keyboard may be implemented in place of a touchscreen 2760 that is part of the display 2755.

[00179] Memory 2730 stores an operating system (not shown) that is executed by CPU 2725 in order to control the overall operation of the therapy controller 2610. According to the principles of the present disclosure, memory 2730 further stores a therapy application program 2731 and a database fde 2732 of selected therapy protocols and operating parameters. During a therapy procedure, the CPU 2725 executes the therapy application program 2731 to cause the therapy controller 2610 to identify the exact product and model of the dressing interface 400 using RFID/NFC transceiver 2735 or camera 2765, or both, depending on the type of product identifier 499 attached to or printed on dressing interface 400. After identifying the correct dressing interface 400, the CPU 2725, under control of the therapy application program 2731, then selects the correct therapy protocol(s) and operating parameters for dressing interface 400 from the database file 2732. CPU 2725 then presents, for example, the proper graphical user interface (GUI) to allow an operator to follow the correct therapy protocol(s) and use the correct operating parameters for the identified dressing interface 400.

[00180] Figure 28 is a method for wirelessly controlling the dressing interface 400 and the therapy system according to an exemplary embodiment of the disclosure. Initially, in 2805, the operator presents the disposable (i.e., dressing interface 400) to the therapy controller 2610, which then reads the product identifier 499. Based on the product identifier and the information in database file 2732, the therapy controller 2610 determines in 2810 if the disposable is genuine and not expired. If the disposable is not genuine or is expired, the therapy controller 2610 in 2815 alerts the user (or operator) and disables therapy until a correct disposable is presented in 2805 and 2810.

[00181] If the disposable is genuine and not expired, the therapy controller 2610 in 2820 determines if the disposable is part of an instillation system. If the disposable is part of an instillation system, the therapy controller 2610 in 2825 will select the correct GUI, the correct help information, and the correct parameter settings for an instillation therapy. [00182] Next, the therapy controller 2610 in 2830 determines if the disposable is part of a negative pressure wound therapy (NPWT) system. If the disposable is part of an NPWT system, the therapy controller 2610 in 2835 will select the correct GUI, the correct help information, and the correct parameter settings for an NPWT therapy.

[00183] Next, the therapy controller 2610 in 2840 determines if the disposable is part of a wound specific system (e.g., surgical incision, bum, blunt trauma, laceration, etc.). If the disposable is part of a wound specific system, the therapy controller 2610 in 2845 will select the correct GUI, the correct help information, and the correct parameter settings for a wound specific therapy, such as incision management therapy.

[00184] If the disposable is not for an instillation system or an NPWT system, the therapy controller in 2860 will alert the user to try again or to try a different disposable. Otherwise, once the therapy controller 2610 has determined the disposable is part of an instillation system and/or a NPWT system, the therapy controller in 2865 may allow the user (or operator) to adjust the settings to suit the specific application and commence therapy.

[00185] As noted previously, bridging is a recognized technique for providing simultaneous negative pressure therapy to neighboring, non-contiguous wounds or to a very large wound using multiple wound dressings, such as dressing interface 400. However, the geometries and locations of the wounds may prevent a bridge from delivering satisfactory instillation therapy to the wounds. The present disclosure describes a system for synchronizing or coordinating a group of negative pressure and/or instillation therapy units, wherein the multiple units provide therapy to a single patient.

[00186] For ease in clinician workflow and a consistent treatment regimen, the multiple therapy units provide synchronized negative pressure therapy. The disclosed system permits the clinician to designate a first therapy unit as the master and one or more additional therapy units as the slave units. The clinician may then select therapy settings on the master therapy unit and the selected settings are communicated to the slave therapy units. When the clinician initiates therapy on the master therapy unit, the slave therapy units also initiate therapy, as well. This master-slave configuration of therapy units permits coordination of negative pressure delivery. Routine events, like purges, may be scheduled as simultaneous occurrences. Uikewise, coordinated responses to off-nominal events (blockages, leaks, etc.) may be made.

[00187] Figure 29 is a functional block diagram of an example embodiment of multiple therapy controllers 2910A and 2910B that can provide coordinated negative-pressure therapy and instillation to multiple wounds in accordance with this specification. Although Figure 29 depicts the use of two therapy controllers, this is by way of illustration only and should not be construed to limit the scope of the disclosure. In alternate embodiments, more than two therapy controllers may be linked to provide coordinated negative pressure therapy and instillation. The disclosed multiple therapy controllers 2910A and 2910B provide a grouping of devices that collectively apply negative pressure therapy and/or instillation therapy to multiple wounds on a single patient. Communication between multiple therapy controllers 2910A and 291 OB that are applied simultaneously to a patient may be established and maintained over long range wireless links (e.g., Wifi, cellular, etc.) and short range wireless links (e.g., Bluetooth, Zigbee, optical, etc.) or by a combination of long and short range wireless links. The disclosed multiple therapy controllers 2910A and 291 OB also provide the capability of selecting and configuring grouped devices. Configurable parameters may include therapy settings and/or timing of negative pressure and instillation.

[00188] In Figure 29, therapy controllers 2910A and 2910B are similar to any one of therapy controllers 2210, 2310, 2410, or 2610. In the specific embodiment in Figure 29, therapy controller 2910A and 2910B may be implemented in the form of a tablet device, such as an iPad tablet or an Android tablet, that controls a therapy device 100 (not shown) that provides negative pressure therapy and instillation therapy. However, this is by way of illustration only and should not be construed to limit the scope of the disclosure. In alternate embodiments, each one of therapy controllers 2910A and 2910B may be an embedded controller in therapy device 100. In the embodiment in Figure 29, therapy controller 2910A receives user inputs from a clinician or other operator. The therapy controller 2910A controls the provision of both negative pressure therapy and instillation to the dressing interface 400A, which is applied to the leg of the patient. Similarly, the therapy controller 2910B controls the provision of both negative pressure therapy and instillation to the dressing interface 400B, which is applied to the torso of the patient.

[00189] In some embodiments, the therapy controller 2910A may function as the primary (or master) therapy controller, while the therapy controller 2910B may function as the secondary (or slave) therapy controller. To accomplish this, the primary therapy controller 2910A receives from the clinician user inputs that control not only the operation of the primary therapy controller 2910A, but also the operation of the secondary therapy controller 2910B . The user inputs may include, among other things, configurable parameters that control the therapy settings, as well as the timing of negative pressure therapy and instillation.

[00190] The primary therapy controller 2910A uses a two-way wireless link 2950 to relay the user inputs to the secondary therapy controller 2910B and control the operation of secondary therapy controller 2910B. Thus, it is unnecessary for the clinician to directly control and operate the secondary therapy controller 2910B. In this manner, the clinician may use the primary therapy controller 2910A and the secondary therapy controller 2910B to provide negative pressure therapy and instillation simultaneously in a coordinated manner to the dressing interface 400A and the dressing interface 400B.

[00191] Dressing 400A comprises a first dedicated sensor assembly similar to the sensor assembly 425 (or 2125) in Figure 21. Dressing 400A is coupled by tubing to a first therapy system 100 (not shown) that provides negative pressure therapy and instillation therapy and is controlled directly by therapy controller 2910A. Dressing 400B comprises a second dedicated sensor assembly similar to the sensor assembly 425 (or 2125) in Figure 21 that is distinct from the first dedicated sensor assembly 425 associated with dressing 400A. Dressing 400B is coupled by tubing to a second therapy system 100 (not shown) that provides negative pressure therapy and instillation therapy and is controlled by therapy controller 2910B via user inputs that are relayed through therapy controller 2910A.

[00192] The therapy controller 2910A receives and processes data from the first sensor assembly 425, such as data related to fluids provided to the tissue interface. Such data may include the type of instillation solution prescribed by a clinician, the volume of fluid or solution to be instilled to the tissue site, and the amount of time needed to soak the tissue interface before applying a negative pressure to the tissue site. The therapy controller 2910A may also control the operation of one or more components of the therapy system 100 to manage the fluids distributed from the solution source 114 for instillation to the first tissue site 150 on the patient’s leg for application to the wound as described in more detail above. In one embodiment, fluid may be instilled to the first tissue site 150 by applying a negative pressure from the negative -pressure source 104 to reduce the pressure at the tissue site 150 to draw the instillation fluid into the dressing 400A. In another embodiment, fluid may be instilled to the tissue site 150 by applying a positive pressure from the negative-pressure source 104 (not shown) or the instillation pump 116 to force the instillation fluid from the solution source 114 to the tissue interface. The therapy controller 2910A may control the fluid dynamics of applying the fluid solution to the tissue interface 108 by providing a continuous flow of fluid or an intermittent flow of fluid for soaking the tissue interface 108. The therapy controller 2910A may apply negative pressure to the tissue interface 108 to provide either the continuous flow or intermittent soaking flow of fluid.

[00193] The therapy controller 2910B receives and processes data from the second sensor assembly 425, such as data related to fluids provided to the tissue interface. Such data may include the type of instillation solution prescribed by a clinician, the volume of fluid or solution to be instilled to the tissue site, and the amount of time needed to soak the tissue interface before applying a negative pressure to the tissue site. The therapy controller 2910B may also control the operation of one or more components of the therapy system 100 to manage the fluids distributed from the solution source 114 for instillation to a second tissue site 150 on the patient’s torso for application to the wound as described in more detail above. In one embodiment, fluid may be instilled to the second tissue site 150 by applying a negative pressure from the negative-pressure source 104 to reduce the pressure at the second tissue site 150 to draw the instillation fluid into the dressing 400B. In another embodiment, fluid may be instilled to the second tissue site 150 by applying a positive pressure from the negative-pressure source 104 (not shown) or the instillation pump 116 to force the instillation fluid from the solution source 114 to the tissue interface. The therapy controller 2910B may control the fluid dynamics of applying the fluid solution to the tissue interface 108 by providing a continuous flow of fluid or an intermittent flow of fluid for soaking the tissue interface 108. The therapy controller 2910B may apply negative pressure to the tissue interface 108 to provide either the continuous flow or intermittent soaking flow of fluid.

[00194] Figure 30 is a functional block diagram of an example embodiment of multiple therapy systems that can provide coordinated negative-pressure and instillation to a large wound in accordance with this specification. Although Figure 30 depicts the use of two therapy controllers, this is by way of illustration only and should not be construed to limit the scope of the disclosure. In alternate embodiments, more than two therapy controllers may be linked to provide coordinated negative pressure therapy and instillation. The disclosed multiple therapy controllers 3010A and 3010B provide a grouping of devices that collectively apply negative pressure therapy and/or instillation therapy to a single large wound on a patient. Communication between multiple therapy controllers 3010A and 301 OB that are applied simultaneously to a patient may be established and maintained over long range wireless links (e.g., Wifi, cellular, etc.) and short range wireless links (e.g., Bluetooth, Zigbee, optical, etc.) or by a combination of long and short range wireless links. The disclosed multiple therapy controllers 3010A and 3010B also provide the capability of selecting and configuring grouped devices. Configurable parameters may include therapy settings and/or timing of negative pressure and instillation.

[00195] In Figure 30, therapy controllers 3010A and 3010B are similar to any one of therapy controllers 2210, 2310, 2410, or 2610. In the specific embodiment in Figure 30, therapy controller 3010A and 3010B may be implemented in the form of a tablet device, such as an iPad tablet or an Android tablet. However, this is by way of illustration only and should not be construed to limit the scope of the disclosure. In alternate embodiments, each one of therapy controllers 3010A and 3010B may be an embedded controller in therapy device 100. In the embodiment in Figure 30, therapy controller 3010A receives user inputs from a clinician or other operator. The therapy controller 3010A controls the provision of both negative pressure therapy and instillation to the dressing interface 400A, which is applied to a large wound on the torso of the patient. Similarly, the therapy controller 3010B controls the provision of both negative pressure therapy and instillation to the dressing interface 400B, which is applied to the same large wound as the dressing interface 400A.

[00196] The therapy controller 3010A functions as the primary (or master) therapy controller, while the therapy controller 3010B functions as the secondary (or slave) therapy controller. The primary therapy controller 3010A receives from the clinician user inputs that control not only the operation of the primary therapy controller 3010A, but also the operation of the secondary therapy controller 3010B. The user inputs may include, among other things, configurable parameters that control the therapy settings, as well as the timing of negative pressure therapy and instillation.

[00197] The primary therapy controller 3010A uses atwo-way wireless link 3050 to relay the user inputs to the secondary therapy controller 3010B and control the operation of secondary therapy controller 3010B. Thus, it is unnecessary for the clinician to directly control and operate the secondary therapy controller 3010B. In this manner, the clinician may use the primary therapy controller 3010A and the secondary therapy controller 3010B to provide negative pressure therapy and instillation simultaneously in a coordinated manner to the dressing interface 400A and the dressing interface 400B.

[00198] The negative pressure therapy and instillation therapy that is provided by primary and secondary therapy controllers may be the same or may be different depending on whether a single large wound is being treated or multiple, separate wounds are being treated. By way of example, in Figure 30, because the same wound is being treated by dressing interface 400A and dressing interface 400B, it is very likely that primary therapy controller 3010A and the secondary therapy controller 3010B will apply the same (or very similar) negative pressure and instillation regimens to dressing interfaces 400A and 400B. However, in Figure 29, because the two different wounds are being treated by dressing interface 400A and dressing interface 400B, primary therapy controller 3010A and the secondary therapy controller 3010B may apply either the same regimens or different regimens to dressing interfaces 400A and 400B.

[00199] In Figure 30, dressing 400A comprises a first dedicated sensor assembly similar to the sensor assembly 425 (or 2125) in Figure 21. Dressing 400A is coupled by tubing to a first therapy system 100 (not shown) that provides negative pressure therapy and instillation therapy and is controlled directly by therapy controller 3010A. Dressing 400B comprises a second dedicated sensor assembly similar to the sensor assembly 425 (or 2125) in Figure 21 that is distinct from the first dedicated sensor assembly 425 associated with dressing 400A. Dressing 400B is coupled by tubing to a second therapy system 100 (not shown) that provides negative pressure therapy and instillation therapy and is controlled by therapy controller 3010B via user inputs that are relayed through therapy controller 3010A.

[00200] The therapy controller 3010A receives and processes data from the first sensor assembly 425, such as data related to fluids provided to the tissue interface. Such data may include the type of instillation solution prescribed by a clinician, the volume of fluid or solution to be instilled to the tissue site, and the amount of time needed to soak the tissue interface before applying a negative pressure to the tissue site. The therapy controller 3010A may also control the operation of one or more components of the therapy system 100 to manage the fluids distributed from the solution source 114 for instillation to the tissue site 150 on the patient’s torso for application to the wound as described in more detail above. In one embodiment, fluid may be instilled to the torso tissue site 150 by applying a negative pressure from the negative-pressure source 104 to reduce the pressure at the torso tissue site 150 to draw the instillation fluid into the dressing 400A. In another embodiment, fluid may be instilled to the tissue site 150 by applying a positive pressure from the negative-pressure source 104 (not shown) or the instillation pump 116 to force the instillation fluid from the solution source 114 to the tissue interface. The therapy controller 3010A may control the fluid dynamics of applying the fluid solution to the tissue interface 108 by providing a continuous flow of fluid or an intermittent flow of fluid for soaking the tissue interface 108. The therapy controller 3010A may apply negative pressure to the tissue interface 108 to provide either the continuous flow or intermittent soaking flow of fluid.

[00201] The therapy controller 3010B receives and processes data from the second sensor assembly 425, such as data related to fluids provided to the tissue interface. Such data may include the type of instillation solution prescribed by a clinician, the volume of fluid or solution to be instilled to the tissue site, and the amount of time needed to soak the tissue interface before applying a negative pressure to the tissue site. The therapy controller 3010B may also control the operation of one or more components of the therapy system 100 to manage the fluids distributed from the solution source 114 for instillation to the tissue site 150 on the patient’s torso for application to the wound as described in more detail above.

[00202] As noted above, therapy controller 3010A and therapy controller 3010B will typically apply the same or very similar negative pressure therapy and instillation therapy when a single large wound is being treated by dressing 400A and dressing 400B. In some instances, however, different but complementary therapies may be applied. By way of example, therapy controller 3010A may apply instillation therapy using dressing 400A, while therapy controller 3010B, under the controller of therapy controller 3010A, may concurrently apply negative pressure therapy using dressing 400B. In this situation, fluids would be introduced to the wound by dressing 400A and drained by dressing 400B, thereby creating a fluid flow path from dressing 400A to dressing 400B and cleansing the wound.

[00203] Figure 31 is a method for providing coordinated negative-pressure and instillation using multiple therapy systems according to an exemplary embodiment of the disclosure. Initially, dressing interfaces 400A and 400B are powered up at 3110. This may be performed by using an activation switch or removing an insulating tab from battery 424. Once power is applied, sensor assembly 2125 is initialized. Next, at 3115, the primary therapy controller 2910A (or 3010A) and the secondary therapy controller 2910B (or 3010B) establish a communication link (e.g., BLE, WiFi, cellular). Once a communication link is successfully established, the core module 2105 on sensor assembly 2125 illuminates the LED indicator 2130 to provide a visual indicator to the operator that the dressing interface 400 is ready to perform therapy operations.

[00204] In 3120, under the direction of the operator of the primary and secondary therapy controllers, the core modules 2105 begin to capture sensor data in dressing interfaces 400A and 400B. In 3125, the core modules 2105 transmits the sensor data to the primary and secondary therapy controllers. The secondary therapy controller 2910B (or 3010B) relay the sensor data to the primary therapy controller 2910A (or 3010A), so that the primary therapy controller can display the data to the operator and receive operator inputs, such as the configurable parameters for each therapy controller and the timing/synchronization information for negative pressure therapy and installation therapy. At 3130, the primary therapy controller 2910A (or 3010A) transmits to the secondary therapy controller 2910B (or 2010B) the corresponding configurable parameters for each therapy controller and the timing/synchronization information. At 3135, dressing interfaces 400A and 400B perform NPWT therapy and instillation therapy as described above in Figures 1-20.

[00205] While shown in a few illustrative embodiments, a person having ordinary skill in the art will recognize that the systems, apparatuses, and methods described herein are susceptible to various changes and modifications. For example, certain features, elements, or aspects described in the context of one example embodiment may be omitted, substituted, or combined with features, elements, and aspects of other example embodiments. Moreover, descriptions of various alternatives using terms such as “or” do not require mutual exclusivity unless clearly required by the context, and the indefinite articles "a" or "an" do not limit the subject to a single instance unless clearly required by the context. Components may be also be combined or eliminated in various configurations for purposes of sale, manufacture, assembly, or use. For example, in some configurations the dressing 102, the container 112, or both may be eliminated or separated from other components for manufacture or sale. In other example configurations, the controller 110 may also be manufactured, configured, assembled, or sold independently of other components.

[00206] The appended claims set forth novel and inventive aspects of the subject matter described above, but the claims may also encompass additional subject matter not specifically recited in detail. For example, certain features, elements, or aspects may be omitted from the claims if not necessary to distinguish the novel and inventive features from what is already known to a person having ordinary skill in the art. Features, elements, and aspects described herein may also be combined or replaced by alternative features serving the same, equivalent, or similar purpose without departing from the scope of the invention defined by the appended claims.

Claims

CLAIMS What is claimed is:

1. A system for providing negative pressure therapy at a tissue site, the system comprising: a primary therapy controller; a first dressing interface configured to be controlled by the primary therapy controller and to provide at least one of first negative pressure therapy or first instillation therapy at the tissue site; a secondary therapy controller configured to be controlled by the primary therapy controller; and a second dressing interface configured to be controlled by the secondary therapy controller and to provide at least one of second negative pressure therapy or second instillation therapy at the tissue site.

2. The system of claim 1, wherein the primary therapy controller is configured to receive primary user inputs from an operator of the system, the primary user inputs including configurable parameters operable to configure the first dressing interface to provide the at least one of first negative pressure therapy or first instillation therapy at the tissue site.

3. The system of claim 2, wherein the primary user inputs further include timing information operable to configure the first dressing interface to initiate and to halt the at least one of first negative pressure therapy or first instillation therapy at the tissue site.

4. The system of claim 2, wherein the primary therapy controller is configured to receive secondary user inputs from an operator of the system, the secondary user inputs including configurable parameters operable to configure the second dressing interface to provide the at least one of second negative pressure therapy or second instillation therapy at the tissue site.

5. The system of claim 4, wherein the secondary user inputs further include timing information operable to configure the second dressing interface to initiate and to halt the at least one of second negative pressure therapy or second instillation therapy at the tissue site

6. The system of claim 4, wherein the primary therapy controller transmits the secondary user inputs to the secondary therapy controller.

7. The system of claim 6, wherein the primary therapy controller and secondary therapy controller are configured to establish a wireless communication link to enable the primary therapy controller to transmit the secondary user inputs to the secondary therapy controller.

8. A system for providing negative pressure therapy at a plurality of tissue sites, the system comprising: a primary therapy controller; a first dressing interface configured to be controlled by the primary therapy controller and to provide at least one of first negative pressure therapy or first instillation therapy at a first tissue site; a secondary therapy controller configured to be controlled by the primary therapy controller; and a second dressing interface configured to be controlled by the secondary therapy controller and to provide at least one of second negative pressure therapy or second instillation therapy at a second tissue site spaced apart from the first tissue site.

9. The system of claim 8, wherein the primary therapy controller is configured to receive primary user inputs from an operator of the system, the primary user inputs including configurable parameters operable to configure the first dressing interface to provide the at least one of first negative pressure therapy or first instillation therapy at the tissue site.

10. The system of claim 9, wherein the primary user inputs further include timing information operable to configure the first dressing interface to initiate and to halt the at least one of first negative pressure therapy or first instillation therapy at the tissue site.

11. The system of claim 9, wherein the primary therapy controller is configured to receive secondary user inputs from an operator of the system, the secondary user inputs including configurable parameters operable to configure the second dressing interface to provide the at least one of second negative pressure therapy or second instillation therapy at the tissue site.

12. The system of claim 11, wherein the secondary user inputs further include timing information operable to configure the second dressing interface to initiate and to halt the at least one of second negative pressure therapy or second instillation therapy at the tissue site.

13. The system of claim 11 , wherein the primary therapy controller transmits the secondary user inputs to the secondary therapy controller.

14. The system of claim 13, wherein the primary therapy controller and secondary therapy controller are configured to establish a wireless communication link to enable the primary therapy controller to transmit the secondary user inputs to the secondary therapy controller.

15. The system of claim 8, wherein the first negative pressure therapy applied at the first tissue site is substantially different from the second negative pressure therapy applied at the second tissue site.

16. The system of claim 15, wherein the first instillation therapy applied at the first tissue site is substantially different from the second instillation therapy applied at the second tissue site.

17. A method for providing therapy at a tissue site, the method comprising: in a primary therapy controller, receiving from an operator primary user inputs, wherein the primary user inputs include configurable parameters operable to configure a first dressing interface to provide at least one of first negative pressure therapy or first instillation therapy at the tissue site; in the primary therapy controller, receiving from the operator secondary user inputs, wherein the secondary user inputs include configurable parameters operable to configure a second dressing interface to provide at least one of second negative pressure therapy or second instillation therapy at the tissue site; transmitting the secondary user inputs from the primary therapy controller to a second therapy controller that is controlled by the primary therapy controller; in the first dressing interface, applying the at least one of first negative pressure therapy or first instillation therapy at the tissue site under the control of the primary therapy controller; and in the second dressing interface, applying the at least one of second negative pressure therapy or second instillation therapy at the tissue site under the control of the secondary therapy controller.

18. The method of claim 17, wherein the primary user inputs further include timing information operable to configure the first dressing interface to initiate and to halt the at least one of first negative pressure therapy or first instillation therapy at the tissue site.

19. The method of claim 18, wherein the secondary user inputs further include timing information operable to configure the second dressing interface to initiate and to halt the at least one of second negative pressure therapy or second instillation therapy at the tissue site.

20. The method of claim 17, wherein the primary therapy controller and secondary therapy controller are configured to establish a wireless communication link to enable the primary therapy controller to transmit the secondary user inputs to the secondary therapy controller.